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ABSTRACT OF DISSERTATION 
 
 
 
 
 
HIGH DOSE SIMVASTATIN AS A POTENTIAL ANTICANCER THERAPY IN 
LEUKEMIA PATIENTS 
 
 
 
Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor that is used for the treatment of hyperlipidemia. Simvastatin has recently been 
studied for its potential use in cancer therapy. In-vitro studies have shown that 
simvastatin displays anticancer activity, but at concentrations unlikely to be achieved in 
patients being receiving typical antihyperlipidemic treatment doses.  Thus, several 
clinical trials were conducted to study the tolerability of high dose statins in cancer 
patients. The maximum tolerated dose of simvastatin was determined to be 15 
mg/kg/day, 25-fold higher than a typical dose. However, it is not known if simvastatin 
plasma concentrations can reach those found to be effective in-vitro. In this context, we 
initiated a clinical study to determine the pharmacokinetics of high dose simvastatin in 
patients with chronic lymphocytic leukemia. For this purpose, an LC-MS/MS method was 
developed and validated for the quantitation of simvastatin and its acid form in plasma 
and peripheral blood mononuclear cells obtained from CLL patients. Results show that 
simvastatin concentrations were dose proportional relative to the antihyperlipidemic 
doses, but lower than those required for in-vitro cytotoxicity against cancer cells. These 
findings demonstrate that the in-vitro effective concentrations of simvastatin are not 
achievable clinically, which might explain the limited effectiveness of high dose 
simvastatin in this study and in previous clinical trials. In view of these data, the use of 
simvastatin as a sole therapy in cancer treatment was not encouraging and led us to 
examine the use in combination with other anticancer drugs. 
After screening several chemotherapeutic agents in combination with 
simvastatin, we showed that tipifarnib (a farnesyltransferase inhibitor) interacts 
synergistically in several leukemia cell lines. Mechanistically we showed that simvastatin 
augments the cytotoxicity of tipifarnib by disrupting the localization of RAS in the cell 
membrane and by subsequent deactivation of the ERK pathway. Consistent with this 
observation, drug treatment led to the induction of apoptosis through the caspase 
cascade activation and the cleaved PARP upregulation. Notably, this synergistic effect 
was observed at clinically achievable concentrations of simvastatin and tipifarnib. Thus, 
the effectiveness of this combination should be explored further in future clinical studies. 
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Chapter 1 : Introduction 
A. Background 
Statins have become well established as safe and effective drugs in the treatment 
of hypercholesterolemia. The beneficial effects of statins in primary and secondary 
prevention of cardiovascular diseases were demonstrated in several clinical trials, such 
as Scandinavian Simvastatin Survival Study (4S) [1], Long-term Intervention with 
Pravastatin in Ischemia Disease (LIPID) [2], Cholesterol and Recurrent Events (CARE) 
[3] , West of Scotland Coronary Prevention Study (WOSCOPS) [4], Air Force/Texas 
Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) [5] and the Heart 
Protection Study (HPS) [6]. Statins mediate their effect through the inhibition of the 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase, an enzyme of the 
mevalonate pathway. In a rate limiting process this enzyme catalyzes the conversion of 
HMG CoA to mevalonate, the precursor of cholesterol [7, 8]. Thus, statins exert their 
therapeutic effect primarily by decreasing the intracellular hepatic cholesterol levels and 
by upregulating the hepatic LDL receptor expression, which results in an increase of LDL 
cholesterol hepatic uptake and substantial decline in plasma LDL cholesterol levels [7, 
8]. 
The statin family is composed of eight members that are naturally derived or 
chemically synthesized (Figure 1.1). Lovastatin, simvastatin, and pravastatin are 
naturally derived from fungal fermentation, whereas fluvastatin, atorvastatin, cerivastatin, 
rosuvastatin and pitavastatin are synthetically derived. Cerivastatin was withdrawn from 
the market in August 2001 due to risk of serious rhabdomyolysis. All statins possess a 
common structural characteristic which is an HMG-CoA like moiety that enables statins 
to compete with HMG-CoA on the enzyme active site. In all of the statins, this side chain 
moiety exists in an open ring (active, acid) form which is responsible for binding the 
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HMG CoA reductase active site. However, lovastatin and simvastatin are present in a 
lactone prodrug form which undergoes hydrolysis in vivo to the active open ring form by 
carboxyesterases in the liver and plasma.   
B. Statins and Pleiotropic effects 
 The strong correlation between serum cholesterol levels and coronary artery 
disease [9, 10] supported the assumption that the protective effect of statins in 
cardiovascular disease is mainly attributed to the ability of statins to lower the serum 
cholesterol levels. However, this notion seemed to be imprecise when subgroup 
analyses of large clinical trials have suggested possible beneficial effects of statins that 
may not be entirely dependent on cholesterol reduction. For instance, the risk of 
myocardial infarction was found to be significantly lower in individuals treated with statins 
than those treated with other cholesterol lowering agents with both groups showing 
comparable reduction in serum cholesterol levels [11, 12]. Likewise, administration of 
statins was associated with a substantial lower risk of developing dementia relative to 
those treated with other lipid lowering agents. This effect was independent of the 
presence or absence of untreated hyperlipidemia suggesting no central role of LDL 
cholesterol levels in the effect of statins [13]. Moreover, the vascular protective effects of 
statins were demonstrated in a clinical study where four weeks of simvastatin treatment 
improved the endothelial functions in patients with heart failure compared to those 
treated with ezitimibe, despite the comparable levels of LDL cholesterol in both groups 
[14]. Several reports have also demonstrated the association between the use of statins 
and the reduced risk of osteoporosis and multiple sclerosis [15, 16]. In a similar context, 
several studies have reported the association of statins use with decreased risk of 
cancer [17-19]. In a retrospective study, statins significantly reduced the risk of renal cell 
carcinoma by 48% in almost half a million patients, irrespective of age, sex, smoking, 
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and obesity [19]. Conversely, a recent systemic review with 42 studies failed to show 
any evidence on the protective effect of statins in cancer [20]. Conclusions driven from 
these studies were inconsistent which may be attributed to the nature of the studies as 
being observational and retrospective [21]. Long follow up studies might be needed to 
detect any potential long-latency effects of statins in cancer. Overall, these findings 
strongly suggest the possible beneficial effects of statins beyond cholesterol reduction. 
Thus, investigators began to unravel the molecular mechanism and the clinical 
implications of these pleiotropic effects. 
C. Statins and mevalonate pathway 
As mentioned above, statins mediate their anti-hypercholesterolemic effect through 
blocking the mevalonate pathway and subsequent decrease in cholesterol production 
(Figure 1.2). Cholesterol is a vital cell membrane component and its production is 
necessary for cellular membrane structure and integrity. It also acts as a precursor for 
steroid hormones and bile acids synthesis [22]. However, there are several other 
downstream products of the mevalonate pathway such as ubiquinone (coenzyme Q10), 
dolichol and isoprenoids that were found to play a critical role in the different cell 
functions. For instance, Dolichol, in the form of dolichol phosphate, plays an important 
role in glycoprotein synthesis. It works as a carrier molecule of oligosaccharide in N-
linked protein glycosylation. Ubiquinone (coenzyme Q10) is involved in the electron 
transport chain in mitochondrial respiration and functions as an antioxidant in the 
inhibition of lipid peroxidation [23]. Isoprenoids, including geranylgeranyl pyrophosphate 
(GGPP) and farnesyl pyrophosphate (FPP), are used to modify small G proteins such as 
RAS and RHO GTPases that play a crucial role in cell motility, proliferation and survival 
[24]. In fact, several studies demonstrated that most of the pleiotropic effects induced by 
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statins including their antitumor activity are mediated through the depletion of 
isoprenoids and the subsequent impairment of the small G proteins functions [25].  
D. G-proteins  
Guanine nucleotide-binding proteins (G proteins) are a large family of GTP binding 
proteins that act as a molecular switch regulating wide variety of cell functions. There are 
two main classes of G Proteins, the heterotrimeric G proteins (large G proteins) that are 
composed of α, β, and γ subunits and are activated by membrane G proteins coupled 
receptors. The second class is monomeric G proteins that are also known as small G 
proteins or small GTPases because of its low molecular weight of 20 - 40 KDa. Small G 
proteins are classified into five major families including RAS, RHO, RAB, ARF and RAN 
families [26, 27]. 
G proteins are known to alternate between inactive GDP bound and active GTP-
bound states (Figure 1.3) [28, 29] . Switching between GDP and GTP binding 
conformations allow these proteins to function as a molecular switch regulating several 
cellular functions (Figure 1.3) [30] . Several protein classes regulate the activity of the G 
proteins including; Guanine nucleotide exchange factors (GEFs) which stimulate the 
dissociation of GDP from the G proteins and allow GTP binding in a passive rebinding 
process; GTPase activating proteins (GAPs) which acts as negative regulators of G 
proteins activity through accelerating the rate of hydrolysis of GTP to GDP [31, 32].   
E. Small G proteins and Cancer  
Small G proteins comprise a large class of membrane proteins with broadly diverse 
functions. Recent study has indicated approximately 600 genes in the human genome 
that encode proteins with C-terminal CXXX motif, a conserved recognition motif in most 
of the prenylated proteins [33]. However, only more than 100 proteins have been 
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identified to undergo prenylation [34]. The members of the small G protein families were 
shown to play critical role in regulating several cellular responses including signal 
transduction, cytoskeletal organization, and intracellular vesicle trafficking [26] . For 
example, members of the RAS family are essential element in transducing signals 
mediated by the extracellular microenvironment that regulate several fundamental 
processes such as cell growth, proliferation and apoptosis [35-37]; the RHO family 
proteins regulate signaling networks involved in cytoskeletal organization, cell cycle 
progression, gene expression and cell proliferation and survival [38-41]. Both RAB and 
ARF family members are involved in regulating intracellular vesicular transport and 
protein trafficking between different organelles [42, 43], whereas RAN proteins are 
responsible for the transport of RNA and proteins across the nuclear membrane [44, 45].   
Both RAS and RHO GTPases are activated in response to signals, initiated either 
extracellularly or intracellularly, that generate the active GTP-bound form and propagate 
further downstream signaling events. The role of RAS and RHO GTPases in 
carcinogenesis is well established [35]. Constitutive activation of RAS and RHO 
GTPases, either by point mutation or over expression, will trigger downstream signaling 
which are involved in cell growth and proliferation leading to uncontrolled cell growth and 
proliferation and will result in tumor development [35, 38]. In 20 - 30 % of human tumors, 
RAS proteins are constitutively activated by a point mutation that reduces the GTPase 
activity of RAS and prevent the hydrolysis of GTP to GDP [36, 46]. The incidence of the 
mutation of the RAS genes varies greatly among the different tumors, the highest rate of 
mutation was found in pancreatic cancer (90%) [47], colon cancer (50%) [48, 49] and 
lung cancer (30%) [50]. In addition to activation through mutation, RAS was also found 
to be hyperactivated as a result of deregulated expression or by an activating mutation 
of upstream signaling molecules such as growth factor receptor tyrosine kinases. The 
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most common examples are EGFR and HERs that are hyperactivated in many types of 
tumor such as lung, breast and ovarian cancers [51, 52]. Unlike RAS, no work has 
reported activating mutations in RHO proteins; however, accumulating evidence has 
shown that RHO proteins are hyperactivated in human tumors relative to normal tissue 
[39].  
Given the crucial role of RAS and RHO GTPases in regulating several downstream 
pathways that mediate cancer growth and progression, substantial efforts were made to 
target these signaling pathways in cancer therapy. Several therapeutic strategies have 
been developed to inhibit these pathways through blocking the upstream signaling 
molecules or inhibiting the activities of the downstream effectors [53]. One attractive 
approach is to target the RAS and RHO themselves through interrupting their 
posttranslational modification process, which is crucial for the proteins in order to get 
anchored into the membrane and attain full activity. 
F. Post translational modifications of small G proteins 
It was first recognized over twenty years ago that the function of small G proteins is 
dependent on a post-translational modification process that enables small G proteins 
from attaching to the cellular membranes and subsequently being activated [46]. Small 
G proteins are synthesized in the cytosol as hydrophilic soluble proteins that undergo a 
series of modifications in order to add a lipidated hydrophobic moiety that facilitate the 
anchoring of small G proteins into the lipophilic cellular membranes. These modifications 
take place at the CAAX (C, cysteine; A, aliphatic amino acid; X, any amino acid) motif in 
the protein carboxyl terminus at several steps including prenylation, proteolysis and 
carboxymethylation (Figure 1.4). Prenylation is the first and the rate limiting step in the 
modification and it includes the covalent attachment of a lipid isoprenoids moiety into the 
cysteine residue of the CAAX motif through the interaction with either 
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farnesylpyrophosphate (FPP, 15-carbon isoprenoids) or geranylgeranyl pyrophosphate 
(GGPP, 20-carbon isoprenoids), which are intermediate products of the mevalonate 
pathway [54]. In general, proteins carrying leucine or phenylalanine as the X residue in 
the CAAX motif get geranylgeranylated and is catalyzed by geranylgeranyl transferase I 
(GGTase I) enzyme, otherwise the protein gets farnesylated in the presence of farnesyl 
transferase (FTase) enzyme [55]. After prenylation, Rce1 endopeptidase catalyzes the 
cleavage of the three terminal amino acids (AAX) of the proteins and then the 
isoprenylated cysteine will get methylated by the isoprenylcysteine carboxyl 
methyltransferase (ICMT) [56]. N- RAS, H- RAS and K- RAS (4A) isoforms undergo 
additional palmitoylation modification (addition of palmitoyl moiety) at the C-terminus 
besides farnesylation, whereas K- RAS (4B) isoform attaches to the membrane through 
farnesyl moiety and a polybasic, lysine rich, sequence near the terminal cysteine. These 
additional modifications are also critical for the association and stability of the small G 
proteins at cellular membranes. In general, these posttranslational modifications are 
critical for RAS and RHO GTPases to associate with cellular membrane in order to 
execute their biological functions. Given the fact that RAS and RHO GTPases play an 
essential role in carcinogenesis, deactivation of these proteins through targeting their 
posttranslational process is thought to be a promising strategy to fight cancer. Several 
approaches were postulated to target this process either through inhibiting the rate 
limiting enzymes such as FTase and GGTase (using FTase and GGTase inhibitors), or 
by interfering with the mevalonate pathway (using statins), in order to inhibit the 
biosynthesis of FFP and GGPP, which are critical substrates for the prenylation process. 
G. Statins and antitumor activity 
Although most of the epidemiological and meta-analyses reports suggest no 
helpful or harmful effect of statins on cancer risk [20, 21], accumulating evidence from in-
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vitro and in-vivo studies have demonstrated the anti-tumor effects of statins in several 
tumor types [57, 58]. The ability of mevalonate to abrogate the antitumor activity of 
statins indicated the importance of the mevalonate pathway in mediating the antitumor 
activity of statins [59, 60]. In fact, depletion of the intracellular pools of both FPP and 
GGPP, as a result of the upstream inhibition of mevalonate synthesis, with consequent 
dysfunction of small G proteins is suggested to be the underlying mechanism of the 
antitumor activity of statins. This finding was supported by several add back studies that 
demonstrated the ability of GGPP to abrogate the statin induced apoptosis in cancer 
cells, whereas addition of FFP only showed partial reversal [59, 61-64]. Other products 
of the mevalonate pathway including cholesterol, squalene, lanosterol, desmosterol, 
dolichol, dolichol phosphate, ubiquinone and isopentenyladenine were not able to 
reverse the apoptotic effect of statins in cancer cells [59, 61, 65].  
Antitumor effects exhibited by statins include growth arrest, induction of apoptosis, 
inhibition of angiogenesis, and repression of tumor metastases [58, 66]. Statins have 
been shown to induce growth arrest at the G1/S phase in both solid tumors and 
hematologic malignancies [67-72]. Many studies have shown that statins antiproliferative 
effect is mediated through the induction of cyclin dependent kinase inhibitors (CKIs), 
p21Waf1/Clip1 and/or p27Kip1 that downregulate the kinase activity of cyclin-dependent 
kinase 2 (CDK-2), essential for G1/S transition [67, 71, 73].  Statin induced growth arrest 
was shown to be rescued by the addition of mevalonate and GGPP, indicating the role of 
geranylgeranylation inhibition in mediating the cytostatic effect of statins [74, 75].  
Similarly, statin induced apoptosis in different tumor types has been found to be 
abrogated by the addition of mevalonate and geranylgeranyl pyrophosphate (GGPP) 
and was partially reversed by farnesyl pyrophosphate (FPP) [59]. The apoptotic activity 
of statins is thought to be mediated through the disruption of the balance between 
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proapoptotic and antiapoptotic members of the Bcl2 family, which are important 
regulators of cell survival. Downregulation of antiapoptotic proteins (e.g. Bcl2 and Mcl1) 
as well as increasing the expression of proapoptotic protein (e.g. Bax and Bim) was 
associated with lovastatin induced apoptosis in different tumor cells [62, 76]. 
Furthermore, statins were found to induce apoptosis through the activation of caspase 
proteases involved in programmed cell death [77, 78]. However, the molecular 
mechanism by which statins generate apoptosis in tumor cells is not well defined. The 
wide intracellular pool of small G proteins as well as their complicated downstream 
network of signaling pathways makes it difficult to define a specific mechanism of action. 
The downregulation of the Raf/MEK/ERK pathway was suggested to contribute to 
lovastatin mediated apoptosis in AML cells [79]. Conversely, the apoptotic effect of 
statins in both ovarian and breast cancer cells was associated with the activation of JNK 
pathway and the phosphorylation of the transcriptional factor c-Jun [64, 80].  In lung 
carcinoma cells, lovastatin was shown to inhibit the EGF induced EGFR 
autophosphorylation and inhibits the AKT activation by EGF in combination with gefitinib 
[81]. In addition to the in vitro antitumor activity, statins have been shown to have in vivo 
antitumor activity in different animal models where simvastatin was found to have an 
inhibitory effect on the proliferation of human AML cells in SCID mice [82]. Furthermore, 
statins were shown to inhibit the growth of colon tumors in rats and mice [83-85] .  
Building upon the evidential results obtained from both in vitro and in vivo studies 
that indicate the diverse antitumor effects of statins on the different types of tumors, 
clinical investigators were tempted to assess whether this antitumor activity will translate 
into significant clinical benefits.    
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H. Clinical trials of statins  
Several clinical studies investigated the value of statins as an adjuvant treatment, 
at typical doses used in the treatment of hypercholesterolemia, in improving the efficacy 
of standard treatment in cancer. A randomized controlled trial in patients with advanced 
hepatocellular carcinoma suggested that the addition of pravastatin, at a daily dose of 40 
mg, to standard treatment prolonged the median survival to 18 months versus 9 months 
in patients receiving standard treatment only [86]. Other clinical trials have shown that 
the administration of simvastatin improved the efficacy of standard therapies in patients 
with multiple myeloma and non-small cell lung cancer [87, 88]. Similarly, addition of 
simvastatin to irinotecan, 5-fluorouracil and leucovorin (FLOFIRI) modestly prolonged 
the time to progression from 6.7-8.5 months with FLOFIRI alone to 9.9 months in 
patients with metastatic colorectal cancer [89]. In contradiction with previous findings, 
addition of pravastatin to chemotherapy in advanced gastric carcinoma in a phase II trial 
did not improve the outcome in those patients [90]. Likewise, simvastatin, at 40mg/daily, 
could not improve the clinical status in chronic lymphocytic leukemia patients [91]. This 
discrepancy in clinical data of statins at typical doses could be attributed to several 
factors including the tumor type being treated, the limited number of patients in the 
study, or the advanced stage of the disease.  
Furthermore, the safety and tolerability of statins at high doses were assessed in 
limited clinical trials. Lovastatin was found to be safe and well tolerated at maximum 
tolerated doses 25 mg/kg/day and 35 mg/kg/day (with concomitant administration of 
ubiquinone to prevent rhabdomyolysis) in cancer patients [92, 93]. In a phase I trial, 
patients with myeloma or lymphoma were able to tolerate simvastatin at 7.5 mg/kg given 
orally, twice daily for seven consecutive days [94]. These high doses of lovastatin and 
simvastatin are more than 40 and 25 fold higher than the regular dose (40mg/day) used 
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for hypercholesterolemia therapy, respectively. However, further evaluation of statins at 
high doses in phase II trials showed limited efficacy in cancer patients [92, 95-97]. Based 
on those negative results, it becomes important to know whether statins at high doses 
are able to achieve therapeutically effective plasma concentrations. Currently, none of 
the conducted clinical trials looked at the pharmacokinetics of statins at high doses. 
Thus, the work contained in this dissertation characterizes the pharmacokinetics of 
simvastatin given at high doses in cancer patients.  
I. Statins combined with other anticancer drugs 
Given the ability of statins to inhibit the biological function of small GTPases and its 
impact on several important cellular functions, numerous preclinical studies were in favor 
of exploring the potential benefits of statins in combination with other anticancer 
treatments. In addition, using statins in a synergistic or additive combination will give the 
opportunity to utilize reduced concentrations of statins that could be achieved in the 
clinic. Recently, Jakobisiak and Golab have published a review article that includes 
numerous combination studies of statins with other anticancer drugs and discussed their 
clinical relevance [98]. Briefly, statins have been shown to potentiate the effects of 
anticancer drugs from different classes such as 5-fluorouracil, etoposide, anthracycline, 
doxorubicin, cisplatin and paclitaxel [99-104]. It is interesting to note that cerivastatin 
augmented the cytotoxic effect of 5- fluorouracil to a degree that only 10 -500 fold lesser 
concentrations of 5- fluorouracil were required to yield similar effect of the drug alone 
[101]. Likewise, synergistic interactions of statins with anticancer agents were seen at 
much lower concentrations of statins relative to what have been used with statins alone 
[99-104].  Moreover, statins were also shown to potentiate the antitumor activity of 
several molecular targeted therapies such as celecoxib, cetuximab, sorafenib and 
gefitinib [105]. In fact, fluvastatin at clinically achievable concentrations was able to 
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induce synergistic interaction in combination with trastuzumab in breast cancer cells 
[106]. In general, synergistic combination of statins with anticancer drugs may warrant 
dose reduction of statins to clinically achievable concentrations that facilitate a smooth 
transition from the in-vitro settings into clinical application. In this dissertation, a 
combination of simvastatin and tipifarnib at clinically achievable concentrations was 
shown to induce cytotoxic effect in leukemia cells in a synergistic fashion. 
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Figure 1.1. Chemical structures of the statins. 
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Figure 1.2. Overview of the mevalonate pathway, its downstream products and targets for inhibition by statins, 
farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors. 
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Figure 1.3. A schematic of small G protein activation. Small G proteins switch between 
GDP (inactive) and GTP (active) conformations which is controlled by GEF, guanine 
nucleotide exchange factors and GAP, GTPase activating proteins. 
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Figure 1.4. Posttranslational modification of RAS and RHO GTPases. 
Farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) catalyze the 
addition of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) to 
the C-terminus of the small G proteins, respectively. Rce1 endopeptidase removes the 
last three amino acids from the carboxyl terminus. Following the removal of the AAX 
amino acids, the carboxyl terminus is then methylated by isoprenylcysteine carboxyl 
methyltransferase (ICMT). Me, Methyl. 
Copyright © Tamer Ahmed 2013 
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Chapter 2 : Hypothesis and Specific Aims 
The long term goal of our research is to evaluate the clinical utility and prospects of 
simvastatin in cancer therapy. An initial objective for this dissertation work included a 
phase-II clinical trial using high dose simvastatin as a therapy in patients with chronic 
lymphocytic leukemia (CLL). Therefore, our studies used simvastatin as a model drug. In 
efforts to develop statins into the clinic for cancer therapy, limited Phase I and II studies 
have assessed the safety and efficacy of high dose statins in cancer patients. Lovastatin 
has been previously studied in phase-I and phase-II studies, in solid tumors, and 
simvastatin was studied in myeloma and lymphoma patients. However, the 
pharmacokinetics of high dose simvastatin, although vital for its clinical development, 
were not previously defined. Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors and exert their anticancer effect by inhibiting prenylation 
(lipidation) of low molecular weight GTPases, such as RAS and RHO oncoproteins, 
which play a key role in intracellular cancer cell signaling. In tumor cells, these signaling 
pathways are deregulated and contribute to cell proliferation and inhibit apoptosis. Our 
initial hypothesis was that high dose simvastatin administered for one week every 21 
days for 6 cycles is safe and efficacious in adults with recurrent or refractory CLL. In 
addition, we hypothesized that high dose simvastatin treatment will disrupt the cellular 
localization of proteins that depend on prenylation for their trafficking and will induce 
apoptosis in CLL cells. 
To facilitate the planned clinical study, we first sought to determine the 
pharmacokinetics of simvastatin, as well as its apoptotic effects, in a limited number 
(n=3) of patients that were administered high dose at its MTD (7.5 mg/kg, twice daily, for 
seven days). Therefore we conducted the studies outlined in Specific Aim 1. 
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Specific aim 1: Evaluate the pharmacokinetics of high dose simvastatin in a pilot clinical 
trial in (CLL) patients. 
Aim 1.1: Develop, implement and validate a bioanalytical method for accurate 
and precise quantitation of simvastatin lactone and simvastatin acid in plasma 
and peripheral blood mononuclear cells. This work is outlined in Chapter 3. 
Aim 1.2: Determine the pharmacokinetics and peripheral blood mononuclear 
cells (PBMCs) biodistribution in patients treated with high dose simvastatin. This 
work is outlined in Chapter 4. 
Aim 1.3: Determine whether high dose simvastatin treatment induces apoptosis 
in CLL cells from treated patients. This work is outlined in Chapter 4. 
 
Based primarily on the findings from Aim 1.2, we reconsidered the use of simvastatin as 
a single agent and sought to determine combination treatments that could potentially be 
synergistic. In these studies we focused on combining statin with a farnesyl transferase 
inhibitor (i.e., tipifarnib) which was designed to prevent lipidation (farnesylation) of RAS. 
Our rationale for this combination was based on the capacity of RAS to become lipidated 
by geranylgeranylation, which is a process that can be inhibited by simvastatin. Although 
each drug alone can induce apoptosis, we reasoned that the combination may allow for 
synergistic effects that can be achieved at lower concentrations. Our hypothesis is that 
the combination of simvastatin and tipifarnib is synergistic and this synergy is conferred 
by the capacity of simvastatin to block the alternative lipidation pathway of RAS, which 
induces apoptosis. Therefore we conducted the studies outlined in Specific Aim 2. 
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Specific aim 2: Assess the interaction between simvastatin and tipifarnib in inducing 
cytotoxicity in leukemia cell lines. This work is outlined in Chapter 5. 
Aim 2.1: Determine whether simvastatin synergistically induces apoptosis in 
combination with tipifarnib in leukemia cells. 
Aim 2.2: Determine the underlying molecular mechanisms that induce apoptosis 
in simvastatin/tipifarnib treated cells including RAS membrane localization, 
downstream signaling, and apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Tamer Ahmed 2013 
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Chapter 3 : Validated LC-MS/MS method for simultaneous determination of 
simvastatin and its acid form in human plasma and cell lysate: Pharmacokinetic 
Application 
A. Introduction 
Simvastatin is a well-established drug for the treatment of hyperlipidemia. 
Simvastatin is a prodrug administered in the lactone form, which is converted in the liver 
into the active acid form (Figure 3.1). It is this active carboxylate form that reduces 
cholesterol biosynthesis by competitively inhibiting the 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the mevalonate pathway 
[8]. Additionally, statins inhibit the synthesis of other downstream products in the 
mevalonate pathway, such as the isoprenoids [8]. Isoprenoids, including farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), are known to be 
involved in important cellular processes such as proliferation and apoptosis [24]. Thus, 
statins have recently been tested for their potential use as anticancer agents. As with all 
agents in this class, in vitro studies have shown that simvastatin displays anticancer 
activity, but only at concentrations that are higher than those observed in plasma of 
patients being administered typical doses associated with hyperlipidemia therapy [107].  
Several clinical trials were subsequently conducted to study the safety and 
tolerability of high dose statin analogues, including simvastatin, in cancer patients [92-
94]. Oral statins were found to be well tolerated at high doses with minor side effects. In 
a phase I study, lovastatin given orally at a dose of 25 mg/kg daily was well tolerated 
and safe in patients with solid tumor [93]. In the case of simvastatin, a phase I study in 
patients with myeloma or lymphoma has shown that the maximal tolerated dose (MTD) 
of simvastatin, given orally, is 7.5 mg/kg twice a day, which is 25-fold higher than typical 
dose. The most common side effects of high dose simvastatin were nausea, diarrhea, 
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muscle weakness and myalgia [94]. However, pharmacokinetics (PK) was not defined 
and it is not known if simvastatin plasma concentrations can reach the levels necessary 
for the antitumor activity observed in vitro. In this context, we initiated a clinical study to 
characterize the pharmacokinetics of simvastatin lactone and its acid form in plasma and 
peripheral blood mononuclear cells (PBMCs) after oral administration of simvastatin at 
7.5 mg/kg twice daily in patients with recurrent and refractory chronic lymphocytic 
leukemia (CLL).  
Simvastatin has low systemic bioavailability which is attributed to the high 
extraction by the liver, the main site of action for treating hyperlipidemia. Therefore, 
sensitive analytical methods have previously been developed to assay both simvastatin 
(SIM) and its acid form (SIMA) in plasma [109-112]. The first analytical method 
developed was an LC coupled with UV detection (238 nm); nonetheless,  low sensitivity 
for quantitation of SIM and SIMA in biological fluids was reported [113]. Better sensitivity 
using UV detection was achieved later with an LOQ of 0.5 ng/mL but with run time > 
28.7 min [114]. A more sensitive HPLC-FD method using 1-bromoacetylpyrene for 
derivatization has been reported with an LOQ of 0.1 ng/mL for both analytes [115]. 
Although this LC-FD method is highly sensitive, sample preparation using solid phase 
extraction and analyte derivatization is inconvenient and time consuming. On the other 
hand, several LC-MS/MS methods have been developed for the determination of SIM 
and SIMA in biological fluids which are more sensitive and specific [109-112]. These 
methods are coupled with either solid phase extraction (SPE) or liquid-liquid extraction 
(LLE) procedures. Solid phase extraction has yielded good recoveries for SIM but SIMA 
recovery was low [116]. LLE showed better recoveries for both SIM and SIMA compared 
to SPE [109, 111, 112]. Current analytical methods have not been validated for the 
analyses of SIM and SIMA in cell lysates. Moreover, few assays have been validated to 
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measure plasma concentration of SIM and SIMA at higher levels [117-119]. Here we 
report the development and validation of an LC-MS/MS method for the analysis of 
simvastatin and its acid form in human plasma and PBMCs. 
B. Methods 
1. Chemicals and reagents 
Simvastatin was purchased from Toronto Research Chemicals Inc. (North York, 
Canada). Ammonium acetate (Mallinckrodt Baker, Philipsburg, NJ, USA) and sodium 
hydroxide (EM Science, Gibbstown, NJ, USA) were purchased from VWR (West 
Chester, PA, USA). HPLC grade acetonitrile and diethyl ether were obtained from 
Sigma-Aldrich (St Louis, MO, USA). Lovastatin (Alexis Biochemicals, San Diego, CA, 
USA), hydrochloric acid and glacial acetic acid were from Fisher Scientific (Fair Lawn, 
NJ, USA). Anhydrous ethanol was obtained from IBI Scientific (Peosta, IA, USA). K562, 
a chronic myelogenous leukemia (CML) cell line, was purchased from ATCC (Manassas, 
VA, USA). 
2. LC-MS/MS instrumentation and conditions 
All analyses were performed using an HPLC system consisting of a Shimadzu 
LC-20AD pump and a Shimadzu SIL-20AC VP auto sampler (Shimadzu, Columbia, MD, 
USA). The LC system was interfaced to an API 2000 ESI-MS/MS (Applied Biosystems, 
Foster City, CA, USA). The analytical column used was a Phenomenex Luna C18 (2.0 
mm x 100 mm i.d.; 2.5 µm particle size), connected to a C18 guard column (Phenomenex 
C18, 2.0 mm x 4 mm; 5 µm particle size). An isocratic mobile phase was used consisting 
of 75:25 (% v/v) acetonitrile : ammonium acetate (0.1M, pH 5.0 adjusted with acetic 
acid). The flow rate was 0.15 mL/min under ambient temperature. The auto sampler 
temperature was maintained at 4°C and the injection volume was 20 µL.  The run time 
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was 10 min. All analytes and internal standard were detected on a triple quadrupole 
mass spectrometer (API 2000), equipped with a turbo ion spray source (MDS SCIEX, 
Toronto, Canada) and operating in the positive ion mode. Lovastatin (LOV) was used as 
an internal standard (IS). Quantitation was performed using multiple reaction monitoring 
(MRM) of precursor/product ion transitions at m/z 419.3/199.3 for SIM; 437.3/303.3 for 
SIMA; and 405.2/199.3 for LOV.  
The optimized source parameters for SIM, SIMA and LOV were as follows: the 
nebulizer gas pressure was set at 30 psi, the heater gas at 90 psi, the ion spray voltage 
was 5500 V and the turbo heater temperature was 500°C. The curtain gas pressure was 
set at 40 psi and the collision activation dissociation (CAD) gas at 10 psi. Lastly the 
entrance potential, declustering potential, collision energy and cell exit potential applied 
were set at 8.27, 14, 17 and 5.25 V for SIM, 7, 3.8, 14 and 8.5 V for SIMA and 8.7, 12.5, 
21.2 and 5.4 V for LOV, respectively. All the parameters were controlled by Analyst 
software version 1.4.2 (Applied Biosystems, Foster City, CA, USA). 
3. Preparation of standard and quality control samples 
Stock solutions of SIM, SIMA and LOV (1 mg/mL) were prepared in ethanol. 
Simvastatin acid was prepared by alkaline hydrolysis of simvastatin [120]. Standard 
working solutions of SIM and SIMA were prepared by serial dilution of the appropriate 
stock solutions with mobile phase. Standards were prepared fresh for each run by 
spiking 25 µL of the appropriate working solutions of both analytes and internal standard 
into 425 µL of drug free human plasma to obtain calibration concentrations of 2.5, 5, 10, 
50, 100, 250, 500 ng/mL SIM, 5, 10, 50, 100, 250, 500 ng/mL SIMA and 50 ng/mL LOV. 
Similar to plasma calibration standards, cell lysate calibration standards were prepared 
at calibration concentrations of 2.5, 5, 10, 50, 80, 100, 250 ng/mL SIM, 5, 10, 50, 80, 
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100, 250 ng/mL SIMA and 50 ng/mL LOV. Cell lysate matrix was prepared by lysing 
K562 cells in deionized water (3 x 107 cells/mL) via sonication. 
Plasma quality control (QC) sample concentrations were 7.5, 150 and 400 ng/mL 
for SIM and 15, 150 and 400 ng/mL for SIMA. Cell lysate QC sample concentrations 
were 7.5, 90 and 200 ng/mL for SIM and 15, 90 and 200 ng/mL for SIMA. QC samples 
were prepared using stock solutions other than those used for calibration standards 
preparation. Both calibration standards and QC samples were prepared at 4°C in an ice 
bath. 
4. Processing of plasma and cell lysate samples 
All plasma and cell lysate samples were stored at -80°C and thawed at room 
temperature. A 25 µL aliquot of LOV was added to 475 µL of plasma or cell lysate 
sample in 16 mm x 100 mm glass test tube. The tubes then were vortexed for 10 s. After 
the addition of 500 µL of ammonium acetate buffer (0.1 M, pH 5.0), tubes were vortexed 
again for 1 min.  Diethyl ether (3 mL) was then added to each tube and samples were 
placed on a shaker at 200 rpm for 15 min at 4°C. Extracted samples were centrifuged at 
3000 rpm for 10 min at 4°C. After centrifugation, the aqueous layer was frozen by 
placing the tubes in dry ice for 1 min. The organic layer was decanted into a new 16 mm 
x 100 mm test tube and was evaporated till dryness at room temperature using a gentle 
stream of nitrogen. The residue was reconstituted in 50 µL of mobile phase and 20 µL 
was injected onto the HPLC column. 
5. Method validation 
The method validation of SIM and SIMA in human plasma and cell lysate was 
performed according to the FDA guidelines [121]. The assay was validated for specificity 
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and sensitivity, linearity, precision and accuracy, extraction recovery, matrix effect, and 
stability. 
5.1. Specificity and sensitivity: Assay specificity and sensitivity were conducted in 
eight different lots of blank plasma that was either left blank or spiked with both analytes 
and IS. Analytes were extracted using the previously described extraction procedure and 
analyzed to determine the extent of interference by endogenous plasma components at 
the retention time of both analytes and IS. The lowest limit of quantitation (LLOQ) was 
assessed in the same plasma lots used for specificity. The determination of LLOQ was 
based on the criteria that the deviation of the measured concentrations should not be 
more than 20% from the nominal concentration and that the signal to noise ratio be ≥ 5.  
5.2. Linearity: Linearity was evaluated using plasma samples spiked with both 
SIM and SIMA at concentration ranges of 2.5-500 ng/mL and 5-500 ng/mL, respectively. 
The internal standard, LOV, concentration was 50 ng/mL in all calibration standards. 
Three calibration curves were prepared and analyzed by plotting area ratios of analyte to 
internal standard against the concentration of each calibration standard. The results 
were fitted into a linear regression model using (1/y) as a weighting factor for both SIM 
and SIMA. A cell lysate calibration curve was prepared similar to plasma calibration 
curve, but at concentration ranges of 2.5-250 ng/mL and 5-250 ng/mL for SIM and SIMA, 
respectively. 
5.3. Precision and accuracy: The intra-day precision and accuracy was evaluated 
at three different QC levels (low, medium and high) in eight replicates on the same day 
and in five replicates on three different days for inter-day precision and accuracy 
determination.  Acceptable deviation was set within 15% of the nominal concentration for 
accuracy and within 15% relative standard deviation for precision.  
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5.4. Extraction recovery and matrix effect: The recovery efficiency of the 
extraction procedure was performed at low and high QCs using the extraction procedure 
described in section 2.4. Recovery was evaluated as a percentage of the peak area of 
analytes that were spiked into a matrix before extraction to the peak area of analytes 
that had been spiked after extraction of a blank matrix. Endogenous substances present 
in biological matrix can possibly enhance or suppress analyte ionization to affect the 
sensitivity, precision or accuracy of the described method. Matrix effect was assessed as 
a percentage of the peak areas of control plasma extracted and then spiked with 
analyte, to neat standards injected directly in the same reconstitution solvent. Matrix 
effect was carried out on five different lots of blank plasma and at low and high QC 
levels. 
5.5. Stability: The short term and long term stability of SIM and SIMA in plasma 
and cell lysate samples was evaluated under different storage conditions. All stability 
experiments were performed at low and high QC levels. Both analytes were spiked 
individually in order to assess the potential for interconversion between the lactone and 
acid forms. 
Short term stability of SIM and SIMA was evaluated in plasma and cell lysate 
samples at 4°C (ice-bath) for 6 h.  The autosampler storage stability was determined by 
storing the reconstituted QC samples for 6 h under autosampler conditions (i.e., 4°C). 
Samples were stored for a month at -80°C to evaluate long term stability of SIM and 
SIMA. Lastly, the stability of SIM and SIMA in plasma and cell lysate samples was 
assessed after repeated cycles of freeze and thaw (2 cycles). In each cycle the samples 
were removed from -80°C storage and allowed to thaw at room temperature.  
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6. Pharmacokinetic study 
In a pilot clinical trial, patients received an oral dose of 7.5 mg/kg simvastatin 
twice daily for one week. Only patients who signed a written consent form were enrolled 
in this study. Blood samples (8 mL) were collected after the first oral dose of simvastatin 
at pre-dose, 0.25, 1, 2, 3, 6, 8, and 12 hours.  All samples were collected in heparinized 
BD Vacutainer Cell Preparation Tubes (CPT) and immediately centrifuged (1800 x g for 
30 min at room temperature) to separate plasma and PBMCs. Collected plasma and 
PBMCs were stored at -80°C until analysis. At time of analysis, PBMC pellets were 
thawed and lysed in 1 mL deionized water via sonication then processed as described in 
section 4. 
C. Results and Discussions 
1. Performance of LC and MS/MS 
The Phenomenex Luna C18 column, used in this study, gave a symmetric peak 
shape for all analytes with an acceptable run time (10 min). Mobile phase components 
were selected based on previous works where ammonium acetate was used to enhance 
ionic strength of the analytes [110]. Also, different volumetric ratios of acetonitrile and 
ammonium acetate buffer were tested to obtain the best peak shape for both analytes 
with reasonable retention time (<10 min). In previously developed methods, simvastatin 
and lovastatin (Figure 3.1) were detected in positive ion mode whereas negative ion 
mode was typically favored for simvastatin acid detection [109, 110, 112]. Few studies 
have utilized the positive ion mode for detecting simvastatin acid [117, 118]. However, in 
our studies simvastatin acid gave better fragmentation in positive ion mode with higher 
product ion signal intensities. Thus, both analytes (SIM and SIMA) and IS (LOV) were 
detected in positive ion mode without the need to switch polarity during the sample run. 
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MS source parameters, as well as analytes parameters, were optimized to achieve the 
highest signal intensity.  
2. Selectivity and sensitivity (LLOQ) 
Plasma samples from eight different sources were tested for the presence of 
endogenous substances that might interfere at the retention times of peaks of interest as 
evaluated by chromatograms of blank plasma and cell lysate, plasma and cell lysate 
spiked with SIM and SIMA at QC1 level or LOV at 50 ng/mL, plasma and PBMCs 
collected from patients at predose and 12 h after receiving simvastatin at 7.5 mg/kg 
twice daily (Figure 3.2). Both SIMA and SIM were well separated with retention times of 
2.65 and 7.1 min, respectively. LOV was detected at 5.6 min. The chromatograms show 
no interfering peaks at the retention times of both analytes and IS in the blank plasma. 
However, in-source lactonization of SIMA into SIM was recognized as shown in Figure 
3.2 B, where a small peak (Peak 1) can be seen on the simvastatin MRM channel (m/z 
419.3/199.3) at the retention time of SIMA. A similar peak (Peak 2) occurs on the 
simvastatin acid MRM channel (m/z 437.3/303.3) at the retention time of SIM, this peak 
was explained as the interference of A+1 isotope from [M+NH4]
+ of the simvastatin 
lactone form but not by in-source hydrolysis [122]. Therefore, chromatographic 
separation between SIM and SIMA is needed to eliminate the contribution of the post 
column in-source lactonization and the interference of [M+NH4]
+ isotope of simvastatin 
lactone.  
The LLOQ was tested at different levels ranging from 1-10 ng/mL and it was 
found to be 2.5 ng/mL for SIM with an accuracy of 97% and 8% precision while SIMA 
showed an LLOQ of 5 ng/mL with 105% accuracy and 7% precision. Previous analytical 
methods have proven to be highly sensitive with a limit of quantitation ranging from 0.05-
0.1 ng/mL [109, 110, 112, 117]. These methods developed for the determination of low 
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SIM and SIMA plasma levels achieved by typical doses (40 mg). However, our method 
is developed for PK study of high dose simvastatin that is 25 fold higher than typical 
doses, thus LLOQ achieved was sufficient for the purpose of this study.  
3. Linearity, precision and accuracy 
The calibration curves of SIM (2.5-500 ng/mL) and SIMA (5-500 ng/mL) in human 
plasma and SIM (2.5-250 ng/mL) and SIMA (5-250 ng/mL) in cell lysate showed 
acceptable linearity.  These ranges encompassed the concentrations observed in human 
plasma and PBMCs collected in a pharmacokinetic study following the oral 
administration of high dose simvastatin. Calibration curves (n= 3) prepared in human 
plasma yielded the following regression equations y= 0.005 (±0.001) + 0.61(±0.03) x 
with R2=0.997 and y= 0.002 (±0.002) + 0.23 (±0.02) x with R2=0.997 for SIM and SIMA, 
respectively. Similarly, calibration curves (n= 3) prepared in cell lysate yielded the 
following regression equations y= 0.003 (±0.002) + 0.65 (±0.11) x with R2=0.997 and y= 
0.001 (±0.002) + 0.31 (±0.09) x with R2=0.992 for SIM and SIMA in cell lysate, 
respectively.  
Inter- and intra-day precision and accuracy were determined at three 
concentration levels (7.5, 200 and 400 ng/mL for SIM and 15, 90 and 150 ng/mL for 
SIMA). As shown in Table 3.1, inter- and intra-day precision values of SIM and SIMA, 
expressed as % relative standard deviation (RSD), ranged from 1.1 to 5.3%, whereas 
accuracy values ranged between 88.6 - 110.2%. The results from intra and inter-day 
precision and accuracy indicate that the method reproducibility is acceptable within the 
same day and on different days. 
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4. Recovery and matrix effect 
Analytes were extracted from biological samples using a liquid-liquid extraction 
procedure; several organic solvents were tested for their extraction efficiencies such as 
methyl tertiary butyl ether (MTBE), diethyl ether, ethyl acetate, acetonitrile and methanol. 
Ethyl acetate showed fair recovery for SIM, but extraction efficiency for SIMA was poor. 
MTBE and diethyl ether were found to have comparable extraction efficiencies for both 
SIM and SIMA and were higher than those obtained by the other organic solvents used. 
Although MTBE was commonly used in previous methods, diethyl ether was chosen for 
LLE procedure in this study. Mean recovery values of SIM and SIMA in human plasma 
were found to be 75.3% and 73.2% at QC1 level whereas at QC3 level they were 68.6% 
and 58.9%, respectively. In cell lysate, mean recovery of SIM and SIMA were higher at 
QC1 levels compared to plasma recovery with 95.7% and 98.1%, respectively. Recovery 
values of both SIM and SIMA in cell lysate at QC3 level were similar to those in human 
plasma. Furthermore, mean matrix effect values are within the acceptable range for both 
SIM and SIMA, indicating that the matrix effect has no impact on the analytes 
quantification. The results of the recovery and matrix effect are summarized in Table 3.2. 
5. Stability 
The interconversion between simvastatin and simvastatin acid is a result of 
hydrolysis of SIM and lactonization of SIMA. It has been found that the interconversion 
can be reduced either at low temperature or when pH is adjusted between pH 4 and pH 
5 [116]. Acidified samples stored under low temperature conditions display very low 
interconversion ( <1% at 4°C and 0.05% at -20°C for 4 weeks) [116]. Thus, during 
method validation, the plasma and cell lysate samples were kept at 4°C at all stages of 
analysis and the reconstitution solution was buffered at pH 5. As shown in Table 3.3, 
simvastatin and simvastatin acid were found to be stable in human plasma, cell lysate 
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and the buffered reconstitution solution for at least 6 h at 4°C.  For long term stability, 
both analytes were stable in human plasma and cell lysate for at least one month at -
80°C (Table 3.4). Over two freeze-thaw cycles of human plasma and cell lysate, SIM 
and SIMA were also found to be stable (Table 3.5). 
Stability of SIM and SIMA in stock and working solutions has been tested in 
several previous works. Over different solutions compositions both SIM and SIMA were 
found to be stable for at least one month [109, 112, 116, 117]. However, we have tested 
the stability of both SIM and SIMA in working solution kept at -80°C, and they were 
found to be stable for at least one year. Lastly, no stability studies were carried out for 
lovastatin as it has previously been shown to be stable under similar storage conditions 
[123].  
6. Pharmacokinetic study 
This method was successfully applied for the determination of simvastatin and its 
acid form in human plasma and PBMCs samples collected from leukemia patients 
following the oral administration of high dose simvastatin. Figure 3.2 shows the MRM 
chromatograms of both plasma and PBMCs samples collected from a patient 12 h after 
receiving simvastatin at 7.5 mg/kg twice daily. Figure 3.3 depicts a typical 
pharmacokinetic profile of SIM and SIMA in plasma and SIM in PBMCs from a CLL 
patient who received high dose simvastatin. Unlike SIM, SIMA concentrations in PBMCs 
were below the detection limit of the assay at all the time points of the PK study. This 
could be attributed to the hydrophilicity of the carboxylate form which may limit its 
accessibility to the PBMCs. Alternatively, the carboxylate may be subject to efflux by an 
ATP-binding cassette transporter.  
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D. Conclusions  
In conclusion, an LC-MS/MS was developed and validated for the determination 
of simvastatin and its acid form in human plasma and cell lysate. This assay is the first 
method developed for the analysis of SIM and SIMA in cell lysate. Moreover, this assay 
spans the concentration range of quantification of both SIM and SIMA that is applied for 
high dose simvastatin administration. Overall, this analytical method has proved to be 
successful for the analysis of SIM and SIMA in plasma and PBMCs samples collected 
from a high dose simvastatin pharmacokinetic study.  
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Figure 3.1. Chemical structures of (A) simvastatin, (B) simvastatin acid and (C) 
lovastatin. 
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Figure 3.2. Representative chromatograms of: blank plasma (A) and cell lysate (F), 
plasma (B) and cell lysate (G) spiked with both SIM and SIMA at QC1 level, plasma (C) 
and cell lysate (H) spiked with LOV at 50 ng/mL, patient plasma (D) and PBMCs (I) 
samples collected at predose and patient plasma (E) and PBMCs (J) samples collected 
12 h after oral administration of simvastatin (7.5 mg/kg). 
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Table 3.1.Intra- and Inter-day precision and accuracy  
Analyte 
Nominal 
concentration  
(ng/mL) 
Intra-day (n=8) 
 
Inter-day (n=5) 
Accuracy  
(mean ± SD, %) 
Precision 
(%RSD)  
Accuracy 
 (mean ± SD, %) 
Precision 
(%RSD) 
Simvastatin 
      
QC1 7.5 110.2 (±5.7) 5.2 
 
96.5 (±2.5) 2.6 
QC2 150 105.2 (±1.4) 1.4 
 
97.1 (±2.4) 2.4 
QC3 400  99.6 (±2.1) 2.1 
 
94.7 (±2.3) 2.4 
Simvastatin acid 
      
QC1 15 95.3 (±3.0) 3.2 
 
92.9 (±4.9) 5.3 
QC2 150 89.4 (±1.0) 1.1 
 
90.3 (±2.3) 2.5 
QC3 400 86.8 (±2.1) 2.4 
 
91.1 (±1.4) 1.5 
SD, standard deviation. RSD, Relative standard deviation. 
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Table 3.2. Recovery and matrix effect 
Analyte 
 
Recovery (mean ± SD, %)  (n=3) 
 
Absolute matrix effect 
 (mean ± SD, %) (n=5) Human plasma Cell lysate 
 
Simvastatin 
     
 QC1 
 
75.3 (±5.8) 95.7 (±4.1) 
 
98.9 (±3.3) 
 QC3 
 
68.6 (±5.4) 67.5 (±7.6) 
 
99.0 (±5.6) 
Simvastatin acid 
     
 QC1 
 
73.2 (±4.4) 98.1 (±5.8) 
 
96.4 (±3.9) 
 QC3 
 
58.9 (±4.1)   63.8 (±10.1) 
 
98.7 (±1.0) 
SD, standard deviation. 
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Table 3.3. Short term stability of the analytes in mobile phase extract, human plasma and cell lysate stored  at 4°C (n=3) 
  
Analyte concentrations at different time points (mean ± SD) a 
Analyte 
 
Mobile phase extract 
 
Human plasma 
 
Cell lysate 
  
1h 3h 6h 
 
1h 3h 6h 
 
1h 3h 6h 
Simvastatin 
  
QC1 
 
99.7 
(±6.7) 
106.7 
(±11.8) 
102.7 
(±10.2)  
96.6 
(±4.0) 
99.8 
(±14.4) 
101.9 
(±8.8)  
118.9 
(±11.7) 
121.9 
(± 21.6) 
109.9 
(±10.7) 
 QC3 
 
100.3 
(±2.4) 
101.0 
(±2.9) 
97.9 
(±2.8)  
94.0 
(±4.7) 
113.5 
(±3.0) 
115.7 
(±0.6)  
97.1 
(±12.0) 
110.4 
(± 11.8) 
97.3 
(±8.6) 
Simvastatin acid 
  
 QC1 
 
101.2 
(±4.6) 
89.6 
(±3.2) 
92.8 
(±3.7)  
85.5 
(±24.6) 
94.5 
(± 8.5) 
102.8 
(±13.5)  
121.0 
(±16.8) 
111.9 
(± 8.6) 
101.1 
(±9.2) 
 QC3 
 
100.0 
(±3.9) 
98.3 
(±1.8) 
96.8 
(±3.1)  
95.0 
(±10.4) 
97.4 
(±10.1) 
97.5 
(±2.9)  
89.9 
(±1.2) 
81.4 
(± 3.4) 
90.3 
(±3.0) 
a Analyte concentrations are expressed as the mean percentage of time zero concentrations (± standard deviation). 
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Table 3.4. Long term stability in human plasma and cell lysate (n=3) 
Analyte 
 
Analyte concentrations at different time points (mean ± SD) a 
 
Human plasma 
 
Cell lysate 
 
1 Day 3 Days 1 Week 2 Weeks 4 Weeks 
 
1 Day 1 Week 2 Weeks 4 Weeks 
Simvastatin 
  
QC1 
 
105.5 
(±7.6) 
95.6 
(±9.4) 
102.5 
(±10.9) 
99.6 
(±5.2) 
97.0 
(±6.5)  
99.7 
(±7.8) 
90.2 
(±9.2) 
98.3 
(±4.8) 
90.5 
(±5.7) 
QC3 
 
112.1 
(±9.4) 
97.3 
(±3.6) 
102.3 
(±2.6) 
101.4 
(±18.3) 
95.4 
(±11.9)  
87.4 
(±4.4) 
106.5 
(±8.4) 
99.9 
(±5.2) 
101.6 
(±9.2) 
Simvastatin acid 
  
QC1 
 
91.3 
(±7.7) 
106.1 
(±13.4) 
105.9 
(±11.0) 
106.8 
(±6.5) 
91.3 
(±16.4)  
97.1 
(±5.6) 
104.3 
(±8.7) 
104.5 
(±3.2) 
114.7 
(±7.1) 
QC3 
 
99.1 
(±7.3) 
106.5 
(±3.6) 
96.7 
(±2.2) 
106.9 
(±17.3) 
108.3 
(±7.2)  
90.4 
(±14.0) 
96.2 
(±9.4) 
83.0 
(±13.2) 
96.2 
(±12.5) 
aAnalyte concentrations are expressed as the mean percentage of time zero concentrations (± standard deviation). 
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Table 3.5. Freeze and thaw stability in human plasma and cell lysate (n=3) 
Analyte  
Analyte concentrations at given cycle (mean ± SD) a 
Human plasma 
 
Cell lysate 
 
1st cycle 2nd cycle 
 
1st cycle 2nd cycle 
Simvastatin 
  
QC1 
 
113.9 (±11.8) 103.7 (±4.7) 
 
101.5 (±10.0) 95.6 (±5.1) 
QC3 
 
 102.9 (±5.1) 104.5 (±5.1) 
 
88.7 (±6.5) 100.3 (±10.1) 
Simvastatin acid 
  
QC1 
 
   85.4 (±4.9)    95.1 (±16.5) 
 
91.4 (±5.3)  109.9 (±6.8) 
QC3 
 
 96.5 (±11.7)  90.3 (±3.3) 
 
86.1 (±6.9)  105.3 (±3.3) 
aAnalyte concentrations are expressed as the mean percentage of time zero concentrations 
(± standard deviation). 
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Figure 3.3. Pharmacokinetic profiles of (A) simvastatin lactone and carboxylate in 
plasma and (B) simvastatin lactone in PBMCs after oral administration of high dose 
simvastatin in a CLL patient. SIM concentration in PBMCs is normalized to the protein 
concentration of each PBMCs sample. 
 
 
 
 
 
Copyright © Tamer Ahmed 2013 
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Chapter 4 : Pharmacokinetics of high dose simvastatin in refractory and relapsed 
chronic lymphocytic leukemia patients 
A. Introduction 
Over the past two decades, statins have been used safely and effectively for the 
treatment of hypercholesterolemia and for lowering the incidence of cardiovascular 
disease. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate 
limiting enzyme at the top of the mevalonate pathway, which is responsible for 
cholesterol synthesis [7, 8]. In addition to cholesterol, the mevalonate pathway yields 
other downstream products such as isoprenoids, dolichol and ubiquinone [7, 8], which 
are critical components for a wide range of cellular metabolic and signaling processes. In 
particular, isoprenoids (farnesyl pyrophosphate and geranylgeranyl pyrophosphate) are 
crucial for the anchoring of small GTPases, such as RAS and RHO family proteins, to 
the cell membrane. Membrane attachment allows the subsequent activation of these 
proteins, which mediate intracellular signaling for several downstream survival and 
proliferation processes [24].  
In this context, statins have been tested for their potential use as anticancer 
agents in several tumor types. Several reports have shown that statin mediated inhibition 
of isoprenoid synthesis disrupts small GTPases localization to the membrane and is 
likely the underlying mechanism for the in vitro observed antitumor activity [59, 75, 79]. 
Notably, these reports have demonstrated that statins display anticancer activity only at 
concentrations higher than those observed in plasma of patients being administered 
typical doses associated with hyperlipidemia therapy [107].  
Therefore, clinical investigators were prompted to study the safety and tolerability 
of high dose statins in cancer patients. In a lovastatin phase-I study in patients with solid 
tumors, the maximum tolerated dose of lovastatin was 25 mg/kg daily [93]. One minor 
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response was also reported in a patient with recurrent high grade of glioma. In this 
study, the peak plasma concentrations of lovastatin were in the range of 0.1 to 3.9 µM, 
which are comparable to its IC50 values in glioma cells (0.2 - 2 µM) [124].  However, in a 
subsequent phase I/II study of high dose lovastatin in patients with malignant glioma 
only one partial response and one minor response were observed out of nine patients 
[95].  A later phase II study, in patients with advanced gastric adenocarcinoma, tested 
the effect of an even higher lovastatin dose (35 mg/kg/day), by using concomitant 
administration of ubiquinone to prevent rhabdomyolysis, but the results were 
negative[92]. In the case of simvastatin, a phase I study was conducted in patients with 
myeloma or lymphoma and the maximum tolerated dose (MTD) of oral simvastatin was 
determined to be 7.5 mg/kg twice a day, for seven days. The most common side effects 
of high dose simvastatin were nausea, diarrhea, muscle weakness and myalgia [94]. 
However, the study design did not include pharmacokinetics and it remains unknown 
whether simvastatin at high doses can reach the concentrations required for the 
antitumor activity observed in vitro. In a subsequent phase II study, simvastatin at MTD 
was given for 7 days followed by rapid intravenous diffusion of vincristine (0.4 mg), 
adriamycin (9 mg/m2), and dexamethasone 40 mg orally (VAD) on days 7- 10. High dose 
simvastatin failed to reverse clinical resistance to VAD chemotherapy in myeloma 
patients [97]. Authors of this study attributed the limited efficacy of simvastatin to the 
short period of treatment as well as the treatment strategy. However, failure to reach 
therapeutically effective concentrations might be a possible explanation of these 
unsuccessful clinical results. Here we report the pharmacokinetics of simvastatin given 
at MTD in patient with recurrent and refractory chronic lymphocytic leukemia (CLL).  
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B. Methods 
1. Materials 
Simvastatin for in vitro studies was purchased from Toronto Research Chemicals 
Inc. (North York, Canada). Ammonium acetate (Mallinckrodt Baker, Philipsburg, NJ, 
USA) was purchased from VWR (West Chester, PA, USA). HPLC grade acetonitrile and 
diethyl ether were obtained from Sigma-Aldrich (St Louis, MO, USA). Lovastatin (Alexis 
Biochemicals, San Diego, CA, USA) and glacial acetic acid were from Fisher Scientific 
(Fair Lawn, NJ, USA). Heparinized BD Vacutainer Cell Preparation Tubes CPT tubes 
were purchased from Becton-Dickinson (Franklin Lakes, NJ). RPMI 1640 medium, 
penicillin/streptomycin, MEM vitamins and MEM non-essential amino acids were from 
Life Technologies (Grand Island, NY) whereas fetal bovine serum was obtained from 
Atlanta Biologicals (Lawrenceville, GA). 
2. Study Design and subjects 
Eligible subjects were at least 18 years old and diagnosed with CLL utilizing 
WHO classification criteria [125].  All patients had previously received treatment and 
either had refractory or relapsed CLL. At the time of treatment subjects had either 
disease-related symptoms or progressive disease with deterioration of blood counts, 
discomfort from lymphadenopathy or hepatosplenomegaly, recurrent infections, or 
associated autoimmune disorders that necessitated further therapy.  Patients were 
required to have a normal serum bilirubin level and serum transaminase levels of no 
more than 50% above the upper limit of institutional normal limits. All patients provided 
written informed consent for this study, which was approved by the institutional review 
board of the University of Kentucky (Lexington, KY). 
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Simvastatin was administered orally twice daily for seven consecutive days at a 
dose of 7.5 mg/kg per dose.  All doses were administered using 80 mg tablets and were 
rounded to the nearest 80 mg increment.  A 14-day washout followed the seven days of 
treatment comprising a 21-day treatment cycle.  Patients were evaluated for progression 
and unexpected toxicities prior to commencing with each treatment cycle and were to be 
treated for 6 cycles.  All grade 3 or 4 adverse events, except for nausea or diarrhea that 
resolved to less than grade 1 with appropriate anti-emetics or anti-diarrhea medications 
required a treatment reduction.  Additionally, any patient experiencing grade II muscle 
weakness or grade II creatine phosphokinase (CPK) elevation required a dose 
reduction. 
During study treatment, patients underwent weekly or bi-weekly evaluations that 
included history, physical examination, complete blood counts and comprehensive 
chemistry profiles.  Toxicities were graded according to the National Cancer Institute 
Common Toxicity Criteria (version 3.0). The NCI CLL revised guidelines for diagnosis 
and treatment were utilized to determine the level of clinical response [126]. The clinical 
trial was registered with clinicaltrials.gov, NCT00828282, prior to enrolling patients and 
was conducted in compliance with the principles of the Declaration of Helsinki. 
3. Pharmacokinetic study design 
Serial blood samples (8 mL) were collected in heparinized BD Vacutainer Cell 
Preparation Tubes (CPT) tubes during cycle 1 at predose, 15 min and 1, 2, 3, 6, 8, 12, 
and 24 hours and at predose on day 7. Upon collection, samples were immediately 
centrifuged (1800 x g for 30 min at room temperature) to separate plasma and peripheral 
blood mononuclear cells (PBMCs) from whole blood. Top layer (plasma and PBMCs) 
was collected and centrifuged at 1500 rpm for 5 min to separate plasma from PBMCs 
and samples were stored at -80°C until analysis.  
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4. LC-MS/MS Analysis 
An LC-MS/MS method was developed and validated to measure simvastatin and 
its acid form in plasma and PBMCs obtained from CLL patients enrolled in this pilot trial 
[127]. Briefly, all analyses were performed using an HPLC system consisting of a 
Shimadzu LC-20AD pump and a Shimadzu SIL-20AC VP auto sampler (Shimadzu, 
Columbia, MD, USA). The LC system was interfaced to an API 2000 ESI-MS/MS 
(Applied Biosystems, Foster City, CA, USA). Chromatographic analyte separation was 
carried out on a reverse-phase Phenomenex Luna C18 column (2.0 x 100 mm i.d.; 2.5 
µm particle size), connected to a C18 guard column (Phenomenex C18, 2.0 x 4 mm). An 
isocratic mobile phase was used consisting of 75:25 (% v/v) acetonitrile: ammonium 
acetate (0.1M, pH 5.0 adjusted with acetic acid). The flow rate was 0.15 mL/min under 
ambient temperature. The autosampler temperature was maintained at 4°C and the 
injection volume was 20 µL.  The run time was 10 min. All analytes and internal standard 
were detected on a triple quadrupole mass spectrometer, equipped with a turbo ion 
spray source and operating in the positive ion mode. Lovastatin was used as an internal 
standard. Quantitation was performed using multiple reaction monitoring (MRM) of 
precursor/product ion transitions at m/z 419.3/199.3 for simvastatin lactone; 437.3/303.3 
for simvastatin carboxylate; and 405.2/199.3 for lovastatin. All the parameters were 
controlled by Analyst software version 1.4.2 (Applied Biosystems, Foster City, CA, USA).  
For analysis, plasma and PBMC pellets were thawed and PBMC pellets were 
lysed in 1 mL deionized water via sonication. A 25 µL aliquot of lovastatin (2.5 µM) was 
added to 475 µL of plasma or cell lysate sample in 16 x 100 mm glass test tube. The 
tubes then were vortexed for 10 s. After the addition of 500 µL of ammonium acetate 
buffer (0.1 M, pH 5.0), tubes were vortexed again for 1 min.  Diethyl ether (3 mL) was 
then added to each tube and samples were placed on a shaker at 200 rpm for 15 min at 
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4°C. Extracted samples were centrifuged at 3000 rpm for 10 min at 4°C. After 
centrifugation, the aqueous layer was frozen by placing the tubes in dry ice for a minute. 
The organic layer was decanted into a new 16 x 100 mm test tube and was evaporated 
till dryness at room temperature using a gentle stream of nitrogen. The residue was 
reconstituted in 50 µL of mobile phase and 20 µL was injected onto the HPLC column. 
5. Pharmacokinetic data analysis 
Plasma concentrations versus time data were evaluated by compartmental 
modeling using Phoenix WinNonlin 6.2 (Pharsight Corporation, Mountain View, CA). 
Various compartment models were tested to determine the most appropriate model. The 
plasma pharmacokinetic parameters of simvastatin lactone and carboxylate, including 
the maximum observed plasma concentration (Cmax) and time to Cmax (Tmax), terminal 
phase elimination half-life (t1/2) and the area under the plasma concentration-time curve 
(AUC) from time 0 to time of the last measurable concentration (AUCt) were also 
calculated by non-compartmental analysis. PBMCs concentration of simvastatin was 
calculated based on the cellular volume of the collected PBMCs sample with considering 
the volume of CLL cell = 200 fL [128]. CLL cell count in each sample was determined 
through measuring the protein concentration of the sample relative to those obtained 
from standard CLL samples with known cell count.  
6. Specimen collection and CLL cell isolation from PBMCs 
All samples were processed as described above. A portion of the separated 
PBMC pellets was resuspended in FACS buffer (phosphate-buffered saline (PBS), pH 
7.2, 0.5% bovine serum albumin (BSA), and 2 mM EDTA) at concentration of 2 million 
cells/mL. Cells were stained with anti-CD5-PE (2.5 µL) and anti-CD19-FITC (2.5 µL) 
antibodies (Becton-Dickinson, Franklin Lakes, NJ) per 250 µL of suspended cells 
(500,000 cells) in polystyrene tubes. Samples were mixed and incubated for 30 minutes 
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in the dark at 4°C. After incubation cells were washed twice with 1 mL FACS buffer, 
resuspended in 300 µL of buffer and then analyzed using FACScan flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). CLL cells in PBMC samples were both CD5 and 
CD19 positive. If staining was ≥ 85% in the PBMC (i.e., CLL cells represent ≥ 85% of 
PBMCs), the sample was used without any further separation. Otherwise, CLL cells 
were isolated using CD19 microbeads (Miltenyi Biotec, Auburn, CA). 
Briefly, a 20 µL aliquot of CD19 magnetic microbeads was added to 80 µL FACS 
buffer containing 1 x 107 cells. Samples were mixed and incubated for 15 min at 4°C. 
Cells were washed using 1 mL FACS buffer, centrifuged at 300 x g for 10 min, and 
resuspended in 500 µL of buffer. A MACS LS column was used to separate CD19 
labeled cells. After applying the cell suspension, the column was washed with buffer to 
elute unlabeled cells.  CD19 magnetic microbead labeled cells were then flushed out 
from the column by firmly pushing the plunger into the column. The collected CLL cell 
sample was again stained with CD5/CD19 to ensure that the CLL cells were enriched to 
85% or more. 
7. Western blotting 
A portion of the isolated cells collected from CLL patients at pre-dose on day 1 
and day 7 of cycle 1 were washed twice with ice cold PBS buffer. Cell pellets were lysed 
in RIPA buffer (50 mM Tris, pH8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 
1 mM EDTA, 0.1% SDS) supplemented with Complete® protease inhibitor cocktail 
(Roche Diagnostics,  Indianapolis, IN) and incubated for 30 min (4°C) on a rotating 
shaker. Cell lysates were then centrifuged at 1500 rpm for 5 min to remove any 
particulates. Protein concentrations were measured using the BCA protein assay 
(Thermo Scientific, Rockford, IL). Samples were boiled at 95°C for 10 min with NuPage 
LDS sample buffer (Invitrogen, Eugene, OR) and 0.1 M DTT (Sigma, St. Louis, MO). 
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Proteins electrophoresis was performed on 10% SDS-polyacrylamide gel (SDS-PAGE) 
at room temperature and proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Millipore, Billerica, MA) at 4°C. Membranes were blocked for 2 hr at room 
temperature with tris-buffered saline (TBST) or phosphate-buffered saline (PBST) 
containing 0.05% (v/v) Tween-20 and supplemented with 5% (w/v) nonfat milk or BSA.  
Membranes were incubated overnight at 4°C with the following primary antibodies at  
1:1000 dilution: anti-cleaved PARP, Bcl2, phospho ERK, ERK, phospho p38, p38, 
phospho JNK, JNK and GAPDH rabbit polyclonal antibodies (Cell Signaling Technology 
Inc.). After washing with TBST or PBST, the membranes were probed with HRP- 
conjugated secondary antibody for 1 hr at room temperature. Following washes with 
TBST or PBST protein bands were visualized by enhanced ECL (Thermo Fisher 
Scientific, Rockford, IL) using the Kodak Image Station 2000 MM (Eastman Kodak, 
Rochester, NY). 
8. Cell Culture of immortalized cell lines and primary CLL cells 
Primary cultures were derived from the peripheral blood of the CLL patients 
(other than those involved in the clinical trial) with informed consent before therapy. CLL 
cells were isolated from PBMCs as described above. CLL cells were maintained in RPMI 
1640 medium (supplemented with 20% FBS, 1% MEM non-essential amino acids, 1% 
MEM vitamins and penicillin/streptomycin) [129] and were allowed to recover for 24 hr 
before use in the designed experiments. All cultures were maintained at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air.  
9. Cell viability assay 
Primary CLL cells were plated in 96 well plates at a density of 5 x 105 cells per 
well in 100 µL of medium. Cells were incubated with increasing concentrations of 
simvastatin (0 - 200 µM) for 48 hr at 37°C. At the end of the incubation period, 20 μL of 
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MTS reagent (Promega Corporation, Madison, WI) was added to each well and further 
incubated for 4 hr at 37°C. Cell viability was determined by measuring the absorbance at 
490 nm wavelength using Molecular Devices Spectramax M5 plate reader.  
10. Apoptotic assay 
Primary CLL cells (5 x 106 cells/mL) were incubated in a 6 well plate with different 
concentrations of simvastatin (0, 10, 50 and 100 µM) for 48 hr at 37°C. After incubation, 
cells were harvested and washed twice with ice cold PBS buffer. The cell pellet was 
resuspended in Annexin binding buffer (50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2, 
pH 7.4) at a concentration of 1 x 106 cells/mL. To identify dead and apoptotic cells, 1 µL 
propidium iodide (PI) and 5 µL Annexin V-FITC (Invitrogen, Eugene, OR) were added to 
each 100 µL of cell suspension and samples were incubated for 15 min at room 
temperature. Samples were diluted to 500 µL using annexin binding buffer before 
analysis using FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells 
that were positive for Annexin-V but negative for PI were those in early stage apoptosis 
while cells positive for both annexin-V and PI were in late stage apoptosis. 
11. Statistical analysis 
Data are reported as mean values ± SD and analyzed statistically with one-way 
ANOVA followed by Turkey’s post-hoc test. P values ≤ 0.05 were considered significant. 
C. Results 
1. Plasma and PBMCs pharmacokinetics 
Three patients were accrued between July 2009 – January 2011.  The first 
participant accrued, remained on treatment for three cycles of therapy before 
experiencing disease progression.  Of note, this participant reported an initial decrease 
in constitutional symptoms including fatigue and the clinical investigators noted a 
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substantial decrease in the patient’s palpable adenopathy.  Due to the waxing and 
waning nature of CLL, it is unknown if the change in symptoms and adenopathy is 
attributable to the effect of simvastatin.  The subsequent two participants experienced 
progression of leukemia during their first cycle of therapy and were subsequently 
removed from therapy.  One participant experienced grade 1 limb pain as the only 
toxicity attributed to the treatment.  
Simvastatin lactone and carboxylate analyses in plasma and PBMC samples 
were performed using a validated LC/MS/MS assay. Figure 4.1 illustrates the 
chromatograms of simvastatin lactone and carboxylate in plasma and PBMC collected 
from one patient, 1 hr after oral administration of high dose simvastatin.  
As shown in Figure 4.2, simvastatin lactone was more predominant than 
carboxylate in plasma. Non-compartmental analysis using the concentrations from 
Figure 4.2 was initially used to determine the AUC, Cmax, Tmax, and terminal half-life of 
each simvastatin form in these patients and values are summarized in Table 4.1. As 
expected by the low number of patients and the magnitude of the oral dose, we 
observed high interpatient variability in all parameters for both simvastatin lactone and 
carboxylate. Conversely, several structural models were fitted to the plasma data 
obtained from the three CLL patients. In contrast to a previous population study [130], 
two compartment structural model representing only the central compartments of lactone 
and carboxylate did not adequately fit the data of both the second and third patients. 
However, a four compartment model was found to best describe the data and the 
distribution phase of both forms to the peripheral compartment, as depicted in Figure 
4.2. To minimize the number of parameters to be estimated by the model some 
assumptions were made. Based on the previous simvastatin pharmacokinetic studies 
[130, 131], we assumed the interconversion clearance (CL12) of simvastatin lactone to 
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carboxylate to be 40% of the elimination clearance (CL10/F) of the lactone form. 
Furthermore, we considered the reconversion of carboxylate to the lactone form as 
being negligible [131]. Also, both clearances from and to peripheral compartments of 
simvastatin lactone and carboxylate were assumed to be equal (CL13=CL31 ≠ CL24=CL42, 
respectively) and were fixed. Lastly, fixing the absorption rate constant (Ka) at 2.76 1/hr 
[130] as well as the peripheral volume of distribution of simvastatin lactone (V3) or 
carboxylate (V4) was found to improve the fit and the accuracy of the estimated 
parameters. Figure 4.2a and b show the plasma concentration versus time profile of both 
simvastatin lactone and carboxylate after oral administration of simvastatin at 7.5 mg/kg 
to the three CLL patients. 
As shown in Figure 4.2, patient 2 had higher plasma concentrations of both forms 
of simvastatin relative to the other two patients. Simulation of multiple dosing of 
simvastatin based upon the final PK model for 6 days revealed no accumulation of either 
simvastatin lactone or carboxylate after the second dose or at day 6 in the three patients 
(Figure 4.2). The model predicted clearance also showed that there was a 5-fold 
variation in the estimated lactone clearance (i.e., CL/F) (Table 4.1).  
 Similarly, simvastatin lactone and carboxylate was measured in PBMCs and as 
shown in Figure 4.3, patient 2 had the highest concentrations, as compared to the other 
patients, which correlated with their plasma concentrations (R2= 0.9715, Figure 4.4). 
Notably, it was only the simvastatin lactone that was detectable in the PBMC of these 
three patients.  
2. In vivo antitumor activity of simvastatin in CLL patients 
Although simvastatin at high dose showed limited efficacy in all three patients, 
molecular analyses showed that simvastatin had an effect.  Upon treatment with high 
dose simvastatin for 7 consecutive days, CLL cells collected from patient 1 and 2 
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showed elevated level of cleaved PARP (apoptotic marker) expression compared to day-
1 predose sample (Figure 4.5). In fact, the Bcl2 protein is often highly expressed in CLL 
cells and is thought to slow the apoptosis process which leads to their accumulation in 
peripheral blood [132, 133]. Moreover, the MAPK pathways were shown to be important 
regulators of CLL survival [134-137]. Therefore, we examined the effect of simvastatin 
on the expression of Bcl2 as well as MAPKs (p38, JNK and ERK) in CLL cells collected 
from the three treated patients.  As shown in Figure 4.5, simvastatin treatment does not 
seem to affect the expression of Bcl2 protein or any of the MAPK family members in the 
second and third CLL patients. Of note, the first CLL patient showed elevated expression 
of both basal and phosphorylated MAPKs after treatment with simvastatin. 
3. In vitro antitumor activity of simvastatin in primary CLL cells 
The anti-proliferative activity of simvastatin was also assessed in primary cells 
collected from CLL patients using the MTS colorimetric assay. This assay relies on the 
ability of viable cells to actively metabolize the MTS tetrazolium salt into its formazan 
product that has an absorbance measured at 490 nm wavelength.  A dose dependent 
decrease in cell viability of primary CLL cells was observed upon continuous simvastatin 
(0-200μM) treatment for 48 hours (Figure 4.6a). The IC50 values ranged from 47.98-
112.6 µM (Mean ± SD, 94.4 ± 26.6 µM). We next assessed the ability of simvastatin to 
induce apoptosis in primary CLL cells collected from three patients. Similarly, primary 
CLL cells were exposed to increasing doses of simvastatin (0-200 µM) for 48 hours and 
cells were stained with Annexin V and PI. Staining demonstrated a statistically significant 
increase in the percentage of cell apoptosis when treated at 100 µM simvastatin for 48 
hr relative to control (Figure 4.6b).  
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D. Discussion 
Beyond their cholesterol lowering effect, several reports have shown that statins 
have anticancer properties in different tumor types [57, 66]. This effect is believed to be 
mediated through the inhibition of isoprenoid synthesis and the subsequent deactivation 
of small GTPases, which are involved in regulating multiple cellular functions including 
proliferation and survival [75, 79]. However, these in vitro studies have shown that 
statins display their anticancer activity at micro molar concentrations that cannot be 
achieved with typical anti cholesterolemia doses [107]. This provided the rationale for 
testing the safety and tolerability of statins at high doses in cancer patients. Simvastatin 
was well tolerated and its MTD was 7.5 mg/kg twice daily for 7 consecutive days in a 21-
day cycle. This pilot clinical study demonstrated that simvastatin administered at its MTD 
achieved low micro-molar concentrations (Cmax), which based on in vitro evidence, are 
unlikely to be effective.     
Initial attempts to fit the pharmacokinetic data to a two-compartment model, as 
previously reported, were not successful in two of three patients. A four compartment 
model was found to better characterize the data obtained from these patients. However, 
in order for the model to fit the data, several assumptions, based on previous 
pharmacokinetic publications, had to be made. Furthermore, although the model was 
adequately fit to data from day 1, it did not predict the modest accumulation of either 
form of simvastatin, which was observed on day 7. This observed accumulation maybe 
due to slight saturation of metabolic and/or transport processes following the repetitive 
administration of high dose simvastatin.  
Our results are in accord with previous studies of high dose lovastatin. In that 
study, patients with solid tumors were administered lovastatin and the MTD was 25 
mg/kg [93]. As a part of the study pharmacokinetics were conducted and peak plasma 
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concentrations ranged from 0.1-3.9 µM with an average concentration 2.32 µM. These in 
vivo concentrations were found to be comparable to those effective in glioma cells in 
vitro. Nonetheless, this approach did not show success in the clinic where high dose 
lovastatin exhibited limited efficacy in glioma patients in a subsequent phase II trial [95]. 
Although lovastatin is known to cross blood brain barrier [138], it is not known whether it 
can reach the brain at similar concentrations as those achieved in plasma. Similarly, 
simvastatin at its MTD (7.5 mg/kg, given orally, twice a day) failed to reverse clinical 
resistance to VAD chemotherapy (vincristine 0.4 mg, adriamycin 9 mg/m2, and 
dexamethasone 40 mg) in myeloma patients [97]. The short period of treatment (7 days) 
as well as the treatment strategy was denoted as potential factors that contributed to the 
unsuccessful clinical results. However, a longer period of treatment (21 days) with 
lovastatin at 7.5 mg/kg/day did not show any objective responses in patients with head 
and neck squamous cell carcinoma or cervical cancer [139]. Recently, a phase II study 
found no evidence of beneficial effect of high dose simvastatin on disease markers in 
multiple myeloma patients [96]. The investigators of those two clinical studies of high 
dose simvastatin assumed that simvastatin reaches similar concentrations in plasma to 
those achieved with lovastatin. This was a reasonable assumption, since the 
pharmacokinetics of these two statins is similar at lower doses [140] . Although few 
patients were accrued in our study, results from the plasma analysis of simvastatin after 
high dose have proven this assumption. The simvastatin plasma concentrations in our 
patients showed similar but relatively lower Cmax concentrations (0.08 - 2.2 µM) 
compared to lovastatin (Cmax: 0.1 – 3.9 µM). This higher Cmax range of lovastatin is likely 
within the interpatient variability range and may also be attributed to the difference in 
dosage regimen. Lovastatin dosing was more frequent (6.25 mg/kg four times daily) 
relative to simvastatin (7.5 mg/kg twice a day).  Overall, our study was in agreement with 
previous lovastatin studies that reported low micro molar concentrations in plasma after 
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administering high doses [93, 141]. Moreover, the high interpatient variability seen in 
these studies was also observed among patients enrolled in our study which may be 
attributed to several factors including, differences in metabolism,  as well as differences 
in oral absorption, due to efflux or incomplete dissolution of the high doses administered 
[142]. 
The few aforementioned Phase II trials of high dose statins were initiated 
considering the fact that plasma peak concentrations achieved by these doses have 
been shown to be effective in vitro. However, the limited activity of statin seen in these 
clinical trials addresses some concerns about whether statins at high doses are really 
achieving therapeutically effective concentrations at the relevant tissues. Several in vitro 
studies have reported that statins were effective against glioma and myeloma cells at 
low micro-molar concentration ranges 1–10 µM [143-146] and 0.8–13.3 µM [62, 147, 
148], respectively. Noteworthy is the fact that the primary cells collected from glioma and 
myeloma patients were found to be more resistant to statins compared to established 
cell lines. For example, lovastatin were found to inhibit the proliferation of primary cells 
obtained from myeloma patients at 10- 100 µM [149]. Similarly, lovastatin inhibited cell 
proliferation of primary glioma cells at IC50 values ranging from 6 – 63 µM [148], while it 
was shown to induce 10 – 30 % apoptosis in primary cells at 10 µM [150]. Together, 
these observations indicate that the maximum plasma concentrations achieved with high 
dose statins are only approaching the lower range of effective concentrations required 
for anticancer activity in primary myeloma and glioma cells. Therefore, comparing 
effective in-vitro concentrations of statins in established cancer cells with those seen in 
patients may not be a valid approach in these cases. In agreement with this observation, 
our in vitro data indicate that simvastatin induces apoptosis in primary CLL cells only at 
suprapharmacologic concentrations (~100 µM), which are not attainable in vivo. This 
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may in part explain the progression of leukemia in the CLL patients treated with high 
dose simvastatin in this study.  
From another perspective, simvastatin carboxylate is known to be the active form 
that mediates the antitumor activity of simvastatin through the inhibition of the HMG-CoA 
reductase enzyme. In our study, simvastatin carboxylate was found to be present in 
plasma at lower concentrations compared to simvastatin lactone. Moreover, it was not 
observed (or below the detection limit 5 ng/mL (0.01 µM)) in CLL cells isolated from 
these patients, even at high level of exposure as in second CLL patient. The hydrophilic 
nature of the carboxylate form may have hindered its accessibility into CLL cells. In 
general, limited accessibility of the simvastatin active form to the tumor site may be 
considered a critical factor added to other factors that contribute to the poor response 
seen in all the previous clinical trials. Despite the limited efficacy shown in all the CLL 
patients, CLL cells collected form two patients after treatment with simvastatin were 
shown to undergo apoptosis. However, this apoptotic effect was independent of the 
survival pathways of CLL cells, such as MAPK pathways or Bcl2 protein, which were not 
affected by treatment. Interestingly, there was no correlation between level of exposure 
to simvastatin in CLL patients and the molecular apoptotic effect of simvastatin on CLL 
cells isolated from these patients.  
E. Conclusion 
In conclusion, pharmacokinetic data in CLL patients showed that simvastatin 
administered at its MTD achieves plasma concentrations that are far lower than those 
shown to be effective ex vivo in primary CLL cells. In view of these data, the use of 
simvastatin as a sole therapy for treatment of CLL, and perhaps other cancer types, is 
unlikely to be successful. However, rational combination therapy that includes statins 
may still provide clinical benefit.  
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Table 4.1. Pharmacokinetic parameters in plasma for simvastatin lactone and carboxylate after oral administration of MTD of 
simvastatin to CLL patients (n=3). 
PK Parameters Simvastatin lactone*  Simvastatin carboxylate 
 Patient #1 Patient #2 Patient #3 Average (SD)  Patient #1 Patient #2 Patient #3 Average (SD) 
t1/2 (hr) 3.7 3.5 2.1 3.1 (0.8)  3.7 4.1 4.8 4.2 (0.5) 
Cmax (µM) 0.08 2.2 0.42 0.9 (1.1)  0.03 0.6 0.13 0.25 (0.3) 
AUC12 (µM*hr) 0.42 4 1.46 1.9 (1.8)  0.25 1.3 0.93 0.8 (0.5) 
Tmax (hr) 1 1 2 1.3 (0.5)  6 1 3 3.3 (2.5) 
CL/F (L/hr) 1811 375 606 927 (774)  963 440 281 567 (354) 
V/F (L) 12968 292 2046 5102 (6868)  3919 145 15 1363 (2214) 
t1/2: terminal half-life; Cmax: maximum concentration; AUC12: area under the concentration versus time curve for 12 hours; CL: clearance and V: 
volume of distribution; F: bioavailability. 
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Figure 4.1. Representative chromatograms of patient plasma (a) and PBMCs (b) 
samples collected 1 hr after oral administration of simvastatin (7.5 mg/kg). SIM, 
simvastatin lactone and SIMA, simvastatin carboxylate. 
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Figure 4.2. Simulated plasma concentration versus time profiles in CLL patients (n=3) 
after oral administration of simvastatin at MTD regimen (7.5 mg/kg/twice a day), (a) 
simvastatin lactone, SIM (b) simvastatin carboxylate, SIMA. The solid lines represent 
simulated estimated concentrations which were generated using Phoenix WinNonlin 6.2, 
(c) Schematic representation of the final four compartment PK model with first order oral 
absorption.  
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Figure 4.3. PBMCs concentration-time profile of simvastatin lactone following oral 
administration of MTD simvastatin in CLL patients. Simvastatin concentrations were 
normalized to the cellular volume of  CLL cells in each PBMCs sample. SIM, simvastatin 
lactone. CLL cell volume = 200 fL [128]. 
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Figure 4.4. Association of Cmax concentrations of simvastatin lactone in plasma and 
PBMCs of CLL patients. 
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Figure 4.5. Effect of high dose simvastatin on the expression level of MAPK and Bcl-2 
proteins (a) and cleaved PARP protein (b) in CLL cells isolated from patients before and 
after therapy with 15 mg/kg/day simvastatin for 7 consecutive days. CLL cells were 
isolated from treated patients and sorted by FACS (CD5+/CD19+). Cells were processed 
for western blot analysis to assess the expression of JNK, phospho JNK, ERK, phospho 
ERK, p38, phospho p38, Bcl-2 and c-PARP proteins. GAPDH, a cytosol protein, was 
used as a loading control. 
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Figure 4.6. Treatment of CLL patient cells with simvastatin reduces cell viability (a) and 
induces apoptosis (b).  CLL cells were freshly isolated from patients and sorted by FACS 
(CD5+/CD19+). CLL cells were treated for 48 hr with increasing concentrations of 
simvastatin (0-200µM). The percentage of viable cells was measured using MTS assay. 
Apoptosis was measured using Annexin V/PROPIDIUM IODIDE assay and results 
represent percentage of apoptosis (early and late). Data are presented as mean ± SD. * 
P ≤ 0.05. 
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Chapter 5 : Simvastatin interacts synergistically with tipifarnib to induce 
apoptosis in human leukemia cells through the disruption of RAS membrane 
localization and interruption of ERK pathway 
A. Introduction 
The RAS/MEK/ERK signaling pathway encompasses several proteins that play 
key roles in cell proliferation as well as in the prevention of apoptosis of leukemic cells 
[151]. Aberrant regulation of this pathway is observed in leukemia because of RAS 
mutations, which lead to its constitutive activation, as well as genetic alteration of 
upstream signaling molecules of the RAS [152, 153]. Pharmacologic intervention to 
attenuate this pathway is thus a potential therapeutic strategy for leukemia treatment. 
However, it has been difficult to identify molecules that directly inhibit the function of 
RAS, and alternative approaches to prevent or block the membrane localization of RAS 
have been tried as a way to pharmacologically limit the activation of this pathway [24, 
154].  
RAS is a small GTP-binding protein that functions as a molecular switch 
regulating several signaling pathways that play a crucial role in controlling the activity of 
cell proliferation, differentiation and malignant transformation [30, 35-37]. RAS activation 
requires a series of posttranslational modifications to allow its association with the inner 
face of the cell membrane, where it can interact with membrane receptors and activate 
downstream signaling cascades [24]. The first and most crucial step in RAS 
posttranslational modification is the covalent attachment of the farnesyl moiety into RAS 
carboxyl terminal in a process called farnesylation and is catalyzed by the 
farnesyltransferase (FTase) enzyme [24]. 
FTase inhibition was proposed as a strategy to impede RAS localization to the 
membrane and its subsequent activation. Therefore, several farnesyltransferase 
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inhibitors (FTIs) were developed and evaluated in preclinical and clinical settings against 
a variety of human cancers. The preclinical evaluation of FTIs in cell culture and animal 
models has shown promising results as potential therapeutic agents and several FTIs 
progressed into clinical trials [155]. However, the efficacy of FTIs as a single agent in 
patients with solid tumors was limited, but some modest efficacy was observed in 
hematologic malignances [156, 157]. Resistance to FTIs has been attributed to 
posttranslational modification of RAS by an alternative lipidation pathway, whereby  RAS 
can be geranylgeranylated by geranylgeranyltransferase I (GGTase I) in the presence of 
FTIs [158]. This alternative isoprenylation mechanism enables RAS to associate with the 
cell membrane and retain full biologic activity despite of the blockage of the farnesylation 
pathway.  
Understanding the mechanism by which RAS escapes the effect of FTIs tempted 
the investigators to change their strategy by targeting both prenylation pathways in order 
to avoid the cross-geranylgeranylation of RAS and knockdown its activity. Therefore, 
considerable effort has been made to evaluate the FTIs with geranylgeranyltransferase 
inhibitors (GGTI) in combination. Although several studies have demonstrated 
synergistic cytotoxicity and apoptotic activity of FTI/GGTI combinations in different tumor 
types, significant toxicity was reported in preclinical models, which is mostly related to 
GGTI, thereby limiting the therapeutic potential of this combination [159, 160]. Recently, 
GGTI-2418, a novel geranylgeranyltransferase inhibitor, was found to be well tolerated 
with minimal side-effects in a phase I trial in patients with refractory solid tumors [161]. 
Simvastatin , an anti-hyperlipidemic drug that inhibits 3-hydroxy 3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, has been shown in several studies to induce 
apoptosis in cancer cells through blockade of the geranylgeranylation pathway of small 
GTPases [59, 75, 79]. Unlike GGTIs, statins are known to be well tolerated and have a 
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wide margin of safety. Given the ability of simvastatin to inhibit the alternative pathway of 
RAS prenylation as well as its good safety profile, we postulated that simvastatin could 
overcome tipifarnib resistance and augment its antitumor activity in leukemia cells.  
B. Methods 
1. Chemicals  
Simvastatin was purchased from Toronto Research Chemicals Inc. (North York, 
Canada). Tipifarnib was purchased from Selleck Chemicals LLC, Houston, TX, USA. 
Absolute ethanol was obtained from Sigma-Aldrich (St Louis, MO, USA). RPMI-1640 
medium and penicillin/streptomycin were from Life Technologies (Grand Island, NY, 
USA), whereas fetal bovine serum (FBS) was obtained from Atlanta Biologicals 
(Lawrenceville, GA, USA). Alexa Fluor® 488 annexin V/Dead Cell Apoptosis Kit and 
NuPage LDS sample buffer were from Invitrogen (Eugene, OR). Antibodies were 
purchased from Cell Signaling (Danvers, MA ,USA). Mevalonate, farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate were from Sigma-Aldrich (St Louis, 
MO, USA). Propidium iodide was obtained from (Invitrogen Corporation, Carlsbad, CA). 
Riponuclease A from bovine pancreas, resazurin and dithiothreitol (DTT) were 
purchased from Sigma-Aldrich (St Louis, MO, USA). BCA protein assay was from 
Thermo Scientific, Rockford, IL, whereas Complete protease inhibitor cocktail was 
obtained from Roche Diagnostics, Indianapolis, IN. 
2. Cell culture and treatment 
All cell lines (KG1 and HL60 acute myelogenous leukemia; K562, chronic 
myelogenous leukemia; Molt4, Jurkat and HSB2, acute T cell leukemia) were purchased 
from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium 
supplemented with FBS, penicillin (100 IU/mL) and streptomycin (100 µg/mL) at 37°C in 
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a humidified incubator with 5% CO2. FBS was added to medium as follows: 20 % for 
KG1 and HL60 cells, 10 % for Jurkat, Molt4 and HSB2 cells or 5% for K562 cells. 
Cells were suspended in growth medium at 5 x 105 cells/mL for KG1, HL60 and 
HSB2 and 2.5 x 105 cells/mL for K562, Molt4 and Jurkat and placed in 6- well plates and 
treated with simvastatin (1 or 4 µM), tipifarnib (0.1 or 1 µM) or their combinations for 72 
hr. Cells incubated with 10 µL/mL DMSO were used as a control. 
3. Cell viability assay and combination index calculation 
A panel of six cell lines of varied leukemic origin including KG1, HL60, K562, 
Jurkat, Molt4 and HSB2 was used to determine the cytotoxicity of simvastatin and 
tipifarnib following single drug or combination treatment. Cells were placed in 96 well 
plates at a density of 50 x 103 cells per well for KG1, HL60 and HSB2 or 25 x 103 cells 
per well for K562, Molt4 and Jurkat in 100 µL of the appropriate growth medium. Cells 
were incubated with increasing concentrations of simvastatin (0, 0.4 - 400 µM), tipifarnib 
(0, 0.01 – 10 µM) or their combination at different concentrations for 72 hr at 37°C. At 
the end of the incubation period, 10 μL of resazurin was added to each well and further 
incubated for 3 hr at 37°C. Cell viability was determined by measuring the fluorescence 
at 560 nm excitation wavelength and 590 nm emission wavelength using Molecular 
Devices Spectramax M5 plate reader. Synergism between simvastatin and tipifarnib was 
assessed using the combination index (CI) method of Chou and Talalay [162-164]. 
CI= d1/D1 + d2/D2 
In this equation, D1 and D2 represent the doses of drug 1 and drug 2 alone, 
required to produce x% effect, and d1 and d2 are the doses of drugs 1 and 2 in 
combination required to produce the same effect. CI value < 1 indicates synergy while 
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values = 1 or > 1 indicate additivity and antagonism, respectively. Experiments were 
performed in triplicates. 
4. Apoptosis Assay 
Cells were harvested and washed with ice cold phosphate-buffered saline (PBS) 
buffer, pH 7.2. Cell pellets were resuspended (1 x 106 cells/mL) in annexin binding buffer 
(50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2, pH 7.4). To identify dead and apoptotic 
cells, 1 µL propidium iodide (PI) and 5 µL Annexin V-FITC were added to each 100 µL of 
cell suspension and samples were incubated for 15 min at room temperature. Samples 
were diluted to 500 µL using annexin binding buffer before analysis using FACScan flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells that were positive for Annexin-V 
but negative for PI were those in early stage apoptosis while cells positive for both 
annexin-V and PI were in late stage apoptosis. 
5. Cell cycle analysis 
Cells were harvested and washed twice with ice cold PBS buffer. Cells were then 
fixed in 3 mL of absolute ethanol overnight at 4ºC. Cells were washed twice with ice cold 
PBS buffer and incubated with propidium iodide (100 µg/mL) and Ribonuclease A from 
bovine pancreas (200 µg/mL) in the dark for 30 min at 37ºC. Processed samples were 
kept at 4ºC and protected from light until analysis using a FACScan flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). 
6. Total and fractionated protein isolation  
For total lysate preparation, cells were harvested after treatment and washed 
twice with ice cold PBS. Cell pellets were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 
mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM EDTA, 0.1% SDS) 
supplemented with Complete protease inhibitor cocktail and incubated for 30 min (4°C) 
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on a rotating shaker. Cell lysates were then centrifuged at 1500 rpm for 2 min to remove 
any particulates. Protein concentrations of membrane, cytosolic fractions and total cell 
lysate were measured using the BCA protein assay.  
For cytosolic and membrane protein fractions, cells were collected after 
treatment and washed with ice cold PBS buffer. Cells (1x107) were lysed via sonication 
for 15s in 200 µL lysis buffer I (1 mM EDTA, 20 mM Tris-HCl (pH 7.4)) supplemented 
with Complete protease inhibitor cocktail. Lysates were centrifuged at 100,000 x g at 4°C 
for 1 hr using an ultracentrifuge (OptimaMax, TLA55 rotor; Beckman Coulter). The 
supernatant containing the soluble fraction (cytosolic fraction) was collected and the 
pellet (membrane fraction) was then washed with 1 mL lysis buffer I twice, to remove 
any remnant of the cytosolic fraction. The membrane pellet was solubilized in 50 µL lysis 
buffer II (150 mM NaCl, 10 mM Tris-HCl, 5 mM EDTA, 1% Triton X-100) supplemented 
with Complete protease inhibitor cocktail and then sonicated for 5s to solubilize any 
particulate left in the buffer. Protein samples were stored at -20°C until analysis or were 
processed immediately for immunoblotting. 
7. Western blot analysis 
The expression of total-PARP, cleaved PARP, cleaved caspases 3, 7 and 9  and 
procaspases 3, 7 and 9, Bcl2, Mcl1, Bcl-xL, Bax, phospho ERK, total ERK, phospho 
AKT, total AKT, RAS, calnexin  and GAPDH was evaluated in protein lysates or 
subcellular fractions, as indicated. Protein samples were boiled at 95°C for 10 min with 
NuPage LDS sample buffer and 0.1 M DTT. Protein electrophoresis was performed on 
10% SDS-polyacrylamide gels (SDS-PAGE) at room temperature and proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA) at 
4°C. Membranes were blocked for 2 hr at room temperature with tris-buffered saline 
(TBST) containing 0.05% (v/v) Tween-20 and supplemented with 5% (w/v) nonfat milk or 
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bovine serum albumin. Membranes were incubated with primary antibodies overnight at 
4°C at 1:1000 dilution.  After washing with TBST, the membranes were probed with 
HRP- conjugated secondary antibody at 1:2000 dilution (Cell Signaling Technology Inc.) 
for 1 hr at room temperature. Following washes with TBST, protein bands were 
visualized by enhanced ECL (Thermo Fisher Scientific, Rockford, IL) using the Kodak 
Image Station 2000 MM (Eastman Kodak, Rochester, NY). 
8. Statistical analysis 
Data are reported as mean values ± SD and analyzed statistically with one-way 
ANOVA followed by Turkey’s post-hoc test. P values ≤ 0.05 were considered significant. 
C. Results 
1. Simvastatin and tipifarnib combination has a synergistic antiproliferative 
effect in leukemia cell lines 
To evaluate the potential for synergy between simvastatin and tipifarnib we 
treated KG1, HL60, K562, Jurkat, Molt4 and HSB2 cell lines  with either drug alone, to 
determine the respective IC50 (Table A.1 and A.2, Figure A.1 and A.2), and then with 
different concentrations of simvastatin (1 and 4 µM ) and tipifarnib (0.05, 0.1, 0.5 and 1 
µM) in combination. Cell viability was measured after 72 hr of treatment using a 
fluorometric cell proliferation assay as described under methods. Synergism was 
assessed by calculating CI values, which is based on the mathematical model described 
by the Chou and Talalay [162-164]. As shown in Figure 5.1, with the exception of the 
KG1 cells the combination of simvastatin and tipifarnib was synergistic at all 
concentrations. Overall, simvastatin at high dose yielded higher fractional effect (FE) in 
combination with tipifarnib, relative to its lower dose. This effect was more substantial in 
HL60 cells for both CI and FE values. These results indicate that the combination of 
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simvastatin and tipifarnib synergistically enhanced the cytotoxic effects in various 
leukemia cell lines. 
2. The synergistic effects of simvastatin/tipifarnib are mediated by apoptosis 
To determine if the combination of simvastatin/tipifarnib was cytotoxic, we 
investigated whether the reduced cell viability was attributed to apoptosis. Leukemia 
cells were treated with simvastatin (1 or 4 µM) and tipifarnib (0.1 or 1 µM) concentrations 
alone or in combination for 72 hr. Subsequently, western blot analysis was performed to 
analyze the activation of the caspase cascade. As shown in Figure 5.2A, proteolytic 
cleavage of caspase 3 and 7 to their active forms triggered the apoptotic process 
through the cleavage of other important intracellular substrates such as poly 
(ADPribose) polymerase (PARP), which is involved in DNA repair. These results were 
consistent in all leukemia cell lines tested. However, caspase 7 was only activated in 
Jurkat, Molt4 and HSB2 cells. Moreover, we examined caspase 9 activation (cleavage of 
caspase 9), which acts upstream of caspase 3 and 7, using western blot analysis. 
Elevated expression of cleaved caspase 9 was observed in K562, Jurkat, Molt4 and 
HSB2 cells. HL 60 cells showed no expression of both the full length and cleaved forms 
of caspase 7 and 9 and PARP. Conversely, KG1 cells were more resistant to 
simvastatin/tipifarnib with no signs of caspase cascade activation or PARP cleavage.  
In fact, several reports suggest the importance of the antiapoptotic and 
proapoptotic Bcl-2 family proteins in regulating cell survival and apoptosis [165-169]. To 
better understand the apoptotic effect of simvastatin/tipifarnib, we also examined the 
expression of Bcl2 family proteins in leukemia cells treated with simvastatin and tipifarnib 
alone or in combination for 72hr using western blot analysis. As shown in Figure 5.2B, 
combined treatment of simvastatin and tipifarnib did not substantially alter the 
expression of either antiapoptotic (e.g., Bcl2 and Bcl-xL) or proapoptotic (e.g., Bax) 
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proteins. However, simvastatin/tipifarnib resulted in a significant reduction on the 
expression of the antiapoptotic Mcl1 protein in all leukemia cells except KG1. 
To further confirm the apoptosis inducing effect of simvastatin/tipifarnib, Annexin 
V-FITC and PI analysis was performed on a subset of cells. The HL60 and Jurkat cells 
were treated with simvastatin (1 or 4 µM) and tipifarnib (0.1 or 1 µM) alone or in 
combination. As shown in Figure 5.2C and Figure 5.2D, combined treatment of 
simvastatin and tipifarnib showed a significant increase in early (AnnexinV+/PI-) and late 
(Annexin V+/PI+) apoptosis in both cell lines, compared to control and single treatments. 
Together these findings indicate that the synergistic interaction between simvastatin and 
tipifarnib in human leukemia cells is mediated by apoptosis. Also, KG1 was shown to be 
more resistant to this combination than other leukemia types.  
3. Synergistic cytotoxicity of simvastatin/tipifarnib in leukemia cells is not 
associated with cell cycle arrest 
Since the cell proliferation assay cannot distinguish between apoptotic and 
arrested cells, we examined whether cell cycle arrest is contributing to the decrease in 
cell viability following simvastatin/tipifarnib exposure. Leukemia cells including KG1, 
HL60, K562 and HSB2 were treated with simvastatin (4 µM) and tipifarnib (1 µM) alone 
and in combination for 72hr. After treatment, cell cycle distribution was assessed using 
flow cytometry. The distribution of the cell cycle phases (G1, S and G2/M) showed no 
significant changes after treatment relative to control in all leukemia cells tested (Figure 
5.3). These results suggest that the synergetic interaction of simvastatin/tipifarnib is 
cytotoxic and not cytostatic.  
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4. Co-Treatment of simvastatin and tipifarnib disrupts the localization of RAS 
in the cell membrane 
The RAS GTPases are important mediators of cell signaling pathways involved in 
the survival and proliferation of cancer cells. FTI drugs were developed to prevent the 
farnesylation of RAS and thus inhibit its membrane incorporation and ultimately the RAS 
mediated signaling. As reported previously, the limited efficacy of tipifarnib, as well as 
that of other FTIs, may be attributed to the continued signaling of RAS by alternative 
isoprenylation (geranylgeranylation). Mounting evidence suggests that the anticancer 
activity of simvastatin is mediated by its capacity to disrupt the geranylgeranylation of 
small G-protein, primarily RHO proteins [59, 75, 79]. We therefore reasoned that 
coadministration of simvastatin and tipifarnib could disrupt the RAS prenylation process 
and its membrane association through blocking both the farnesylation and the alternative 
geranylgeranylation pathways. Leukemia cells were treated with simvastatin (4µM) and 
tipifarnib (1µM) alone or in combination for 72hr and cells subjected to a fractionation 
procedure to isolate the membrane and the cytosolic protein fractions.  Western blot 
analysis was performed to determine RAS location in both fractions. Interestingly, 
simvastatin/tipifarnib robustly inhibited the membrane association of RAS with its 
subsequent sequestration into the cytosol, Figure 5.4. This effect was not observed in 
KG1 cells where RAS localization in the cell membrane did not change upon treatment 
with the combination compared to the control and single treatments. Overall, these 
findings indicate that simvastatin in the presence of tipifarnib disrupts membrane 
association of RAS and most likely results in loss of RAS function because of its inability 
to associate with membrane bound effectors. 
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5. Simvastatin/tipifarnib downregulates the ERK downstream signaling in 
human leukemia cell lines.  
It is well known that RAS activation is a crucial step for several cytoprotective 
and stress related signaling pathways. Therefore, we examined the effect of 
simvastatin/tipifarnib on the phosphorylation status (activity) of two main RAS 
downstream signaling pathways; ERK and AKT pathways. As shown in Figure 5.5, a 24 
hr treatment of simvastatin/tipifarnib significantly decreased the phosphorylation of ERK 
in three of the tested leukemia cell lines including HL60, K562 and HSB2. Both KG1 and 
Jurkat cells showed no expression of the phosphorylated form of ERK. In addition, only 
Jurkat cells showed high levels of phosphorylated AKT. Interestingly, upon treatment 
with simvastatin alone or in combination the AKT phosphorylation was abolished. This 
result indicates that downregulation of the ERK signaling is most likely because of the 
effect of simvastatin/tipifarnib in disrupting the upstream RAS membrane localization and 
its subsequent deactivation. 
6. Addition of mevalonate and isoprenoids prevents simvastatin/tipifarnib 
induced apoptosis and reverses the disrupted RAS isoprenylation 
To further investigate whether blocking the isoprenylation routes is responsible 
for the apoptotic effect of simvastatin/tipifarnib, leukemia cells were treated with 
mevalonate and isoprenoids (FPP and GGPP) in the presence of simvastatin/tipifarnib. 
Annexin V apoptosis assay and western blot analysis of caspase 3 and Mcl1 were 
employed to assess apoptosis. The Annexin V assay revealed that the apoptotic effect 
of simvastatin/tipifarnib was reversed by the addition of mevalonate, FPP or GGPP in 
HL60 cells (Figure 5.6A and B). Similarly, western blot analysis, in Figure 5.6C, indicated 
that caspase 3 activation (cleaved caspase 3) and Mcl1 downregulation induced by 
simvastatin/tipifarnib, in both K562 and HSB2 cells, were reversed by the addition of 
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mevalonate, FPP or GGPP. On the other hand, the effect of this combination on RAS 
disruption from the membrane was reversed by the addition of mevalonate and GGPP 
and partially by FPP (Figure 5.6D). These findings indicate that simvastatin/tipifarnib is 
mediating its apoptotic effect and RAS membrane disruption through the blocking of both 
the farnesylation and the geranylgeranylation pathways. 
D. Discussion 
Aberrant activation of the oncogenic RAS signal transduction is commonly 
observed in hematological malignancies. RAS mutations have been reported in 30% of 
leukemia, most frequently acute leukemia. FTIs were initially developed to inhibit RAS 
activation through blocking its farnesylation process. Despite the encouraging preclinical 
results, FTIs showed limited activity in clinical trials. This is thought to be due to the 
ability of RAS to get activated through the geranylgeranylation pathway, which acts 
alternatively to the farnesylation pathway once FTIs are administered. This escape 
mechanism was only noticed in K-RAS and N-RAS isoforms, which are commonly 
mutated in solid tumors and leukemia, respectively [158]. Blocking this alternative 
prenylation pathway is an attractive strategy to evade the resistance to FTIs. Here we 
report that simvastatin was able to augment the cytotoxicity of tipifarnib in a panel of 
leukemia cells through blocking the alternative geranylgeranylation pathway of RAS. 
Our data show that simvastatin significantly increased the cytotoxic effect of 
tipifarnib in the different leukemia cells tested. Results from both cell viability and 
apoptotic assays indicate that leukemia cells were differentially affected by the 
simvastatin/tipifarnib combination. The increased sensitivity to this combination was 
more significant in HL60 compared to other leukemia cells tested whereas KG1 cells 
were more resistant with no signs of apoptosis. Our finding was in agreement with 
previous work, which demonstrated that KG1 is one of the insensitive cell lines that 
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required higher doses of simvastatin or tipifarnib relative to other leukemia cell lines 
[170]. Moreover, heterogeneity in response to statins and FTIs in primary CD34+ AML 
cells has been reported recently [171].  
In our studies, we employed AML, ALL and CML cells. With the exception of one 
AML cell line (KG1) the simvastatin/tipifarnib combination was synergistic in all other cell 
lines. However, the observed synergy appears to be independent of RAS mutations.  
Specifically, HL60 (N-RAS mutation, c.182A>T), Molt4 and HSB2 cells (N-RAS mutation, 
c.34G>T) and K562 and Jurkat cells (N- RAS wild type) were all sensitive, while KG1 (N-
RAS mutation, c.35G>A) was resistant. An alternative explanation for the antagonism 
observed in the KG1 cells could be the presence of efflux transporters, such as P-gp and 
BCRP, which could be potentially effluxing the lactone and carboxylate species, 
respectively. However, those proteins were not found in these cells by Western blot 
analyses (data not shown).  This does not preclude the presence of other transporters 
that may limit the accessibility of the simvastatin carboxylate form to the cancer cell. For 
example, MRP1 is an efflux transporter that is ubiquitously expressed and primarily 
transports anionic compounds. Additionally, further studies will be required to assess if 
the KG1 resistance is attributed to deregulated function of the mevalonate pathway.  
Here we determined that the observed synergy following combination treatment 
was due to increased apoptosis. The balance between antiapoptotic (e.g. Bcl-2, Mcl-1 
and Bcl-xL) and proapoptotic (e.g. Bax and Bad) proteins regulates the release of 
cytochrome c from the mitochondria into the cytosol, which will lead to the activation of 
the caspase cascade and the induction of apoptosis. In this study, we demonstrate that 
the simvastatin/tipifarnib combination initiates apoptosis through the downregulation of 
Mcl1 protein. Mcl-1 is an anti-apoptotic member of the Bcl-2 protein family that prevents 
apoptosis by forming heterodimers with proapoptotic Bcl-2 family members. 
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Downregulation of Mcl1 protein allows the proapoptotic Bcl2 proteins to initiate 
mitochondrial collapse and subsequent release of cytochrome c into the cytosol where it 
activates the apoptotic caspase cascade.  Conversely, our results show that Bax 
expression was unchanged by treatment in all cell lines that expressed it.  
In fact, RAS plays a central role in activating several downstream effectors that 
are known to regulate different cell functions including cell growth, survival and 
differentiation. Therefore, therapeutic targeting of RAS signaling pathways has become 
a major endeavor in cancer therapy. Our results demonstrated that disrupting RAS 
membrane localization, by simvastatin/tipifarnib cotreatment, significantly decreased 
ERK phosphorylation in the cell lines tested. This finding is in line with previous work, 
which demonstrated the disruption of RAS/ERK signaling in multiple myeloma cells 
treated with FTI/lovastatin [172]. In general, our results indicate that RAS/MEK/ERK 
pathway might be involved in simvastatin/tipifarnib induced cytotoxicity. However, the 
lack of the basal level of ERK activity in Jurkat cells, which are sensitive to this 
combination, may indicate the involvement of other RAS downstream pathways. 
Conversely, the insensitive cell line KG1 showed no inhibition of RAS isoprenylation 
when treated with simvastatin/tipifarnib combination. Previous report has shown that 
higher concentrations of simvastatin (100 µM) were required to block the isoprenylation 
of RAS in resistant AML cell lines [170]. 
On the other hand, reversal of simvastatin/tipifarnib combination induced 
apoptosis by mevalonate, FPP and GGPP was notably consistent in the sensitive 
leukemia cells. This observation confirms that prenylation pathways are the cellular 
targets of this combination. In line with this finding, RAS membrane disruption was also 
abrogated by the addition of mevalonate and GGPP and partially by FPP. This partial 
effect of FPP could be attributed to the higher binding affinity of tipifarnib to FTase, 
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therefore higher FPP concentrations might be required to completely reverse the effect 
of tipifarnib in this combination. Although, the disruption of RAS prenylation was clearly 
seen upon treatment with simvastatin/tipifarnib combination and was strongly correlated 
with cellular response, RAS as an exclusive target for this combination is still 
questionable. Several reports suggested that RAS may not be the only target for FTI 
treatment and other elusive targets may be involved [173]. The wide pool of proteins that 
undergo prenylation makes it difficult to identify a true therapeutic target for 
simvastatin/tipifarnib. Nonetheless, the ability of GGPP and FPP to rescue the effect of 
simvastatin/tipifarnib combination on the membrane localization of RAS demonstrates 
the role of the alternative prenylation as a mechanism of resistance to tipifarnib 
monotherapy.  
Furthermore, the use of simvastatin as anticancer agent was limited by the high 
doses required to mediate its antitumor activity. However, in our study, simvastatin was 
shown to induce apoptosis in combination with tipifarnib at lower concentrations, as low 
as 1µM. It is interesting to note that simvastatin, given at maximum tolerated dose 
(7.5mg/kg, twice daily) to leukemia patients, was found to achieve plasma levels 
comparable to those used in our study (Chapter 4).  
In summary, the results obtained in this study suggest that synergistic cytotoxic 
effect of simvastatin/tipifarnib combination is, at least in part, due to the disruption of 
RAS membrane localization. Reversal of such effect by the addition of GGPP and FPP 
indicates the role of alternative geranylgeranylation as an escape mechanism for RAS 
activation in the presence of tipifarnib. However, such preliminary evidence of in vitro 
data needs further in vivo investigation. 
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Figure 5.1. Simvastatin synergistically potentiates tipifarnib mediated lethality in human 
leukemia cells. Leukemia cell viability was determined following combination treatment 
with simvastatin (1 or 4 µM) and tipifarnib (0.05, 0.1, 0.5 or 1 µM) for 72 hours. 
Fractional effect (FE) values were determined by comparing results with those of 
untreated controls.  Open and closed circles represent 1 and 4 µM simvastatin treated 
sets, respectively. Numbers from 1 to 4 denote tipifarnib concentrations in ascending 
order.  Results are the mean of 3 independent experiments. 
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Figure 5.2. Combined exposure of leukemia cells to simvastatin and tipifarnib induces 
apoptosis through caspase activation and downregulation of Mcl1. Leukemia cells were 
treated for 72 hours with simvastatin and tipifarnib at concentrations indicated, either 
alone or in combination. At the end of the incubation period, cells were lysed and 
western blot analysis was performed to monitor the cleavage of caspases and PARP (A) 
and the expression of BCL2 family proteins (B).  GAPDH was used as a loading control 
to ensure equivalent loading. Alternatively, HL60 and Jurkat cells were treated with 
simvastatin (4 µM) and tipifarnib (1 µM) alone and in combination for 72hr. Cells were 
then costained with Annexin and PI with subsequent flow cytometric analysis. A 
representative dot-plot is shown for each condition (C). AnnexinV+/PI- stained cells in 
the bottom right quadrant represent early apoptotic cells whereas late apoptotic or 
necrotic cells are located in the upper right quadrant with Annexin+/PI+ staining. In panel 
(D), representative figures of AnnexinV/PI staining of HL60 and Jurkat cells showing the 
sum of the percentages of early and late apoptotic cells. Results represent means of 3 
independent experiments. Data are presented as mean ± SD. *, P > 0.05, significantly 
greater than values for cells exposed to simvastatin or tipifarnib alone. SIM, simvastatin. 
TIP, tipifarnib. 
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Figure 5.3. Simvastatin/tipifarnib does not induce cell cycle arrest in leukemia cells. 
Leukemia cells were treated for 72 hours with simvastatin (4 µM) and tipifarnib (1 µM), 
alone and in combination, before being stained with PI and analyzed by flow cytometry. 
SIM, simvastatin. TIP, tipifarnib 
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Figure 5.4. Simvastatin/tipifarnib alters subcellular localization of RAS in human 
leukemia cells. Leukemia cells were treated with simvastatin (4 µM) and tipifarnib (1 
µM), alone and in combination for 72hrs. Cytosolic and membrane fractions were 
prepared and western blot analysis was performed as described in the method section 
using the indicated antibodies. Calnexin was used as a membrane marker, whereas 
GAPDH is a marker of the cytosolic fraction. SIM, simvastatin. TIP, tipifarnib.  
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Figure 5.5. Co-treatment of simvastatin and tipifarnib blocks ERK phosphorylation in 
human leukemia cells. Upon treatment with simvastatin (4 µM) and tipifarnib (1 µM), 
alone and in combination for 24hr, leukemia cells were processed for western blot 
analysis using the indicated antibodies. GAPDH was used as a loading control. SIM, 
simvastatin. TIP, tipifarnib.  
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Figure 5.6. Depletion of prenyl substrates by simvastatin/tipifarnib is associated with 
apoptosis induction, caspase activation, Mcl1 downregulation and RAS membrane 
disruption. HL60 cells were cotreated with simvastatin (4 µM) and tipifarnib (1 µM) in the 
presence of mevalonate (200 µM), farnesyl pyrophosphate (10 µM) and geranylgeranyl 
pyrophosphate (10 µM). After 72 hour incubation, cells were harvested and costained 
with Annexin V/PI with subsequent flow cytometric analysis. A representative dot-plot 
and bar-figure were shown for each condition (A) and (B), respectively. Alternatively, 
K562 and HSB2 cells were treated similarly and then processed for western blot analysis 
to assess the expression of caspase 3 and Mcl1 (C). GAPDH was used as a loading 
control. Under the same conditions, HL60, K562 and HSB2 cells were processed for 
western blot analysis to monitor the expression of RAS in both the cytosolic and 
membrane fractions (D). Calnexin was used as a membrane marker, whereas GAPDH is 
a marker of the cytosolic fraction. Results represent means of 3 independent 
experiments. Data are presented as mean ± SD. *, P > 0.05, significantly lower than 
values for cells exposed to simvastatin-tipifarnib combination.  SIM, simvastatin. TIP, 
tipifarnib.  
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Chapter 6 : General Discussion 
Statins are inhibitors of 3-hydroxy-3methylglutaryl (HMG) Co-A reductase that 
prevent cardiovascular diseases and lower LDL cholesterol. In recent years, increasing 
evidences from in vitro and in vivo studies have established the antitumor activity of 
statins, independent of cholesterol reduction. Besides their preclinical activity, statins 
have favorable safety profile and are available orally at a relatively inexpensive cost. 
Therefore, investigators were tempted to bring statins into the clinic for cancer therapy. 
However, clinical experience with high dose statins in cancer patients has reported 
unsuccessful outcomes [92, 95-97]. This thesis discusses the clinical utility and 
prospects of statins in cancer therapy. 
As a part of the clinical development of high dose simvastatin in cancer patients, 
understanding the pharmacokinetics of this drug at high doses was important. Our 
pharmacokinetic study is the first to examine simvastatin concentrations in both plasma 
and tumor cells after high dose administration in leukemia patients. In fact, simvastatin at 
maximum tolerated dose (7.5 mg/kg, twice daily) achieved higher plasma concentrations 
(0.08-2.2 µM) relative to a typical dose (40mg) which has a peak plasma concentration 
of 0.02-0.08 µM (10-34 ng/mL). However, the high plasma concentrations achieved are 
still lower than those found to be effective in vitro. These insufficient levels of simvastatin 
are the most likely explanation of the limited efficacy of high dose simvastatin observed 
in previous clinical studies [96, 97]. These low levels of simvastatin are mainly attributed 
to the extensive first pass extraction of simvastatin that hinders the drug reaching the 
systemic circulation at sufficient concentrations. Overall, this poor delivery process of 
statins to the circulation urges further exploration of different strategies to improve 
bioavailability and consequent clinical activity. 
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Most of the clinical studies assessing the antitumor activity of high dose statins, 
have no rationale for the choice of statins. The statin member that is most effective and 
shows favorable clinical profile have yet to be determined. Currently, there are seven 
FDA approved statins in the market that possess the same mechanism of action; 
however, they differ in terms of their chemical structures, pharmacokinetic profiles and 
potencies. In terms of efficacy, preclinical studies have demonstrated that lipophilic 
statins (e.g. lovastatin, simvastatin, atorvastatin, fluvastatin and pitavastatin) have better 
antitumor activity relative to hydrophobic statins (e.g. pravastatin and rosuvastatin) [174-
177], which is logical since lipophilic statins are more accessible to the tumor cells. On 
the other hand, the low systemic bioavailability of statins is considered a major barrier 
that may impede their clinical activity as anticancer agents. In this regard, both 
simvastatin and lovastatin show the lowest bioavailability (below 5%) relative to other 
statin members; yet, they were the most studied statins in clinical trials. Another 
disadvantage of simvastatin and lovastatin is their fast elimination with half-life less than 
three hours. Moreover, simvastatin and lovastatin are substrates for CYP3A4 
metabolizing enzyme [178] that may limit their use in combination with other anticancer 
agents, if a CYP3A4 interaction exists. In view of the poor pharmacokinetic profile of 
both simvastatin and lovastatin, they are unlikely to be considered as an optimal statin 
model for cancer therapy. Therefore, achieving higher bioavailability for prolonged period 
of time is vital for statins in order to score better distribution in the tumor and 
subsequently to attain better efficacy. Fluvastatin, has shown improved bioavailability 
(10-35%) and limited CYP3A4 metabolism; however, the very short half-life of fluvastatin 
(0.5 – 2.3 hr) is a major pitfall that may hold back its clinical development as an 
anticancer therapy. Conversely, pitavastatin, a lipophilic statin recently approved by the 
FDA, shows superior systemic bioavailability (80%) relative to other statins as well as 
longer half-life (11 hours) and limited CYP450 metabolism [178]. Despite of the very few 
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studies that have evaluated the antitumor activity of pitavastatin, its favorable 
pharmacokinetic profile makes it a promising candidate that warrants further evaluation 
in cancer therapy.  
With respect to statin dose, there has been a debate in the last decade about the 
optimal dosage regimen of statins in cancer therapy.  In view of the clinical experience of 
statins in cancer treatment, most of clinical studies have favored continuous 
administration of low dose statins over intermittent high dose regimens in terms of 
safety. Moreover, continuous low dose statin was thought to achieve better efficacy 
through a sustainable blockage of the mevalonate pathway. In fact, most of these 
studies have evaluated the significance of using statins at typical doses as an adjuvant 
treatment in cancer; yet, outcomes turned to be controversial. Of note, high dose statins 
were evaluated in clinical studies as a sole therapy not in combination with standard 
therapy which is the case in low dose statins; thus, it is not clear whether low-dose 
statins is better than high doses in terms of efficacy. 
The lack of clinical benefits of high dose statins in previous studies does not 
preclude that statins at high dose could be useful in combination with other anticancer 
agents. Several preclinical studies have shown the ability of statins to interact 
synergistically with various antitumor treatments [100-104]. Recently, a phase II study 
has evaluated high dose simvastatin in combination with vincristine (0.4 mg), adriamycin 
(9 mg/m2), and dexamethasone 40mg orally (VAD) in a sequential administration [97]. 
Addition of high dose simvastatin showed no response that could be attributed to the 
treatment strategy (sequential versus simultaneous) as well as the short half-life of 
simvastatin. However, in vivo treatment with high dose simvastatin for 7 consecutive 
days in leukemia patients displayed an increase in the in vitro chemosensitivity of their 
AML cells [179].  
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In recent years, the development of molecular targeted therapeutics is dramatically 
evolving over conventional cytotoxic drugs. Many targeted agents that modulate specific 
oncogenic proteins have been approved or still under development with the hope to 
achieve better anticancer activity and fewer side effects. However, the ability of the 
tumor to confer resistance (intrinsic or acquired) against these molecular targeted agents 
is common. Thus, combination therapies become a well-established principle in cancer 
therapy to circumvent cancer resistance. In this thesis, simvastatin was used in 
combination with tipifarnib to evade cancer resistance developed against tipifarnib when 
used alone. Tipifarnib is a farnesyl transferase inhibitor that was initially developed to 
target RAS farnesylation. However, when cells were treated with tipifarnib, K-RAS and 
N-RAS become geranylgeranylated and remain fully functional. Our study showed that 
simvastatin in combination with tipifarnib, at clinically achievable concentrations, 
displayed a synergistic interaction in leukemia. This synergistic combination was based 
on a mechanistic rationale that targets farnesylation pathway of RAS as well as its 
alternative geranylgeranylation pathway. Here we demonstrate that inhibition of both 
prenylation pathways, by combining simvastatin with tipifarnib, induces synergistic 
lethality that was not attained by the inhibition of each prenylation pathway separately.  
Although our study was limited to the in vitro setting and to established cancer cell lines, 
recent study have demonstrated that simvastatin was able to inhibit geranylgeranylation 
pathway in primary AML cells at concentrations similar to those used in our study [179]. 
Generally, these in vitro findings warrant further investigation of high dose statins in 
combination with tipifarnib in leukemia patients. In addition, given the fact that this 
combination was able to knockdown RAS from the cellular membrane, further 
exploration of this combination in other cancer models that harbor K- RAS mutation such 
as pancreatic, colorectal and non-small cell lung cancers is encouraged.  
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It is also worth noting that this combination showed variable response among the 
different leukemia cell lines where AML cell line (HL-60) was the most sensitive one 
toward this combination. This finding is supported by previous work that has reported 
similar heterogeneity in response among group of AML cell lines toward simvastatin, 
tipifarnib or GGTI-298 when they were used separately [170]. The differential sensitivity 
of AML cells was attributed to the difference in interference with prenylation pathways. 
This was in line with our finding that simvastatin/tipifarnib combination was shown to 
disrupt RAS isoprenylation in the sensitive HL-60 cells relative to KG1 cells which were 
more resistant. Interestingly, this heterogeneity in response was observed in primary 
AML cells when treated with simvastatin or FTI/lovastatin. However, further investigation 
is needed to unravel the molecular basis of this differential behavior among AML cells 
and to find whether it can be exploited in the identification of leukemia patient population 
who are most likely to respond for this given combination.  
In conclusion, this thesis provides insights into the clinical feasibility of simvastatin 
and the new approaches of its use in cancer therapy. Using LC-MS/MS analytical tool, 
we have measured simvastatin lactone and carboxylate levels in both plasma and 
PBMCs collected from chronic lymphocytic leukemia patients after high dose 
administration. Despite the limited number of patients enrolled in this pilot trial, our data 
indicate that simvastatin at high doses showed insufficient plasma and tumor 
concentrations which are below those found effective in-vitro. This finding discourages 
the use of high dose statins as a sole therapy in cancer patients, and that, further 
exploration of strategies to improve its clinical activity is required. One promising 
approach is considered in this thesis which is the combination of simvastatin with other 
anticancer agents that may show synergy. Our studies demonstrated a synergistic 
interaction of simvastatin and tipifarnib combination which might be mediated by the 
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RAS/MEK/ERK pathway disruption. These promising preclinical results warrant further 
investigation in other cancer models and in animal models as a step toward future 
clinical application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Tamer Ahmed 2013 
 98 
 
APPENDICES 
Appendix A: Evaluation of the antiproliferative effect of simvastatin and tipifarnib in 
leukemia cell lines. 
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Figure A.1. Dose response curve of simvastatin in human leukemia cell lines. Cell lines, 
KG1 (A), HL-60 (B), K562 (C), Molt4 (D), Jurkat (E) and HSB2 (F) were treated for 72 
hrs with different concentrations of simvastatin (0-400µM). At the end of the incubation 
period, 10 μL of resazurin was added to each well and further incubated for 3 hr at 37°C. 
Cell viability was determined by measuring the fluorescence at 560 nm excitation 
wavelength and 590 nm emission wavelength using Molecular Devices Spectramax M5 
plate reader. Experiments were performed in triplicates. 
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Figure A.2. Dose response curve of tipifarnib in human leukemia cell lines. Cell lines, 
KG1 (A),  HL-60 (B), K562 (C), Molt4 (D), Jurkat (E) and HSB2 (F) were treated for 72 
hrs with different concentrations of simvastatin (0-10µM). At the end of the incubation 
period, 10 μL of resazurin was added to each well and further incubated for 3 hr at 37°C. 
Cell viability was determined by measuring the fluorescence at 560 nm excitation 
wavelength and 590 nm emission wavelength using Molecular Devices Spectramax M5 
plate reader. Experiments were performed in triplicates. 
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Table A.1. IC50 values (µM) of simvastatin in leukemia cell lines (n=3). 
Cell line 
IC50 Values (95%CI)  
Sample# 1 Sample# 2 Sample# 3 Mean (SD) 
KG1 
79.29 
(61.49 to 102.2) 
31.03 
(22.52 to 42.75) 
34.01 
(29.79 to 38.84) 
48.1 (27.0) 
HL60 
17.33 
(14.83 to 20.25) 
9.419 
(8.202 to 10.82) 
12.17 
(10.57 to 14.02) 
12.9 (4.0) 
K562 
15.14 
(10.40 to 22.04) 
10.02 
(7.911 to 12.70) 
5.938 
(4.692 to 7.515) 
10.3 (4.6) 
Molt4 
12.59 
(8.204 to 19.33) 
11.50 
(8.793 to 15.04) 
23.89 
(17.26 to 33.05) 
15.9 (6.8) 
Jurkat 
20.98 
(15.58 to 28.26) 
12.31 
(10.32 to 14.69) 
10.96 
(9.695 to 12.40) 
14.7 (5.4) 
HSB2 
39.08 
(26.54 to 57.56) 
23.47 
(20.49 to 26.88) 
28.34 
(23.22 to 34.59) 
30.2 (7.9) 
 
 
 
 
Table A.2. IC50 values (µM) of tipifarnib in leukemia cell lines (n=3). 
Cell line 
IC50 Values (95%CI)  
Sample# 1 Sample# 2 Sample# 3 Mean (SD) 
KG1 
0.878 
(0.558 to 1.383) 
0.287  
(0.169 to 0.487) 
0.169 
 (0.085 to 0.337) 
0.44 (0.37) 
HL60 
0.208  
(0.135 to 0.322) 
0.414  
(0.266 to 0.645) 
0.650 
 (0.400 to 1.057) 
0.42 (0.22) 
K562 
1.094  
(0.593 to 2.015) 
1.254  
(0.798 to 1.970) 
0.511 
 (0.311 to 0.842) 
0.95 (0.38) 
Molt4 
1.688 
 (1.012 to 2.814) 
1.187 
 (0.659 to 2.136) 
1.201 
 (0.720 to 2.004) 
1.35 (0.28) 
Jurkat 
1.019 
 (0.619 to 1.676) 
0.513  
(0.358 to 0.736) 
0.936 
 (0.660 to 1.329) 
0.81 (0.26) 
HSB2 
0.696 
 (0.483 to 1.003) 
1.041 
 (0.774 to 1.399) 
0.765 
 (0.604 to 0.970) 
0.83 (0.18) 
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